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Abstract 
 
Ovarian cancer is the most lethal gynaecological cancer. About 90% of ovarian cancers are 
epithelial (ovarian carcinomas), thought to arise from the ovarian surface 
epithelium.  Diagnosed usually at clinically advanced stages, many patients show poor 
response to chemotherapy, with resistance and recurrent disease being prevalent. siRNA 
technology is currently being explored in clinical trials as a form of targeted therapeutic 
strategy in the disease.  RBBP6 is a 250kD protein that enhances MDM2-mediated 
ubiquitination of p53 and also plays a role in cell cycle regulation and cell differentiation. It 
is upregulated in numerous cancers such as lung, oesophageal, colorectal and cervical cancer. 
RBBP6 suppresses p53 binding to DNA thereby inhibiting p53-dependent gene transcription.  
RBBP6 was knocked down using 30 nM siRNA in RMG-1 cells for 48 hours, after which the 
cells were treated with 50 nM paclitaxel and 0.5µM camptothecin for 24 hours. xCELLigence 
real time cell analysis was used to evaluate cell proliferation. qPCR and western blot were 
used to evaluate both gene expression and protein expressions respectively, of Bax, Bcl-2, 
MDM2, p53 and p21. Flow cytometry was used to determine the mode of cell death elicited 
apoptosis and also analyse changes in cell cycle progression.  
qPCR and Western blot analyses showed that RBBP6 expression reduced by approximately 
57%. There was a significant upregulation of p53 and a significant downregulation of Bcl-2 
in siRBBP6 transfected cells (p<0.05). Knockdown of RBBP6 resulted in a 37±5.8% cell 
death.   There was a significant increase in cell death in paclitaxel and siRBBP6 co-treated 
cells (81.6±0.79%) as compared to cells treated with paclitaxel only (76.±1.14%). 
siRNA-mediated knock down of RBBP6 induces cell death in RMG-1 ovarian carcinoma 
cells. In addition, paclitaxel-induced cell death in RMG-1 cells is potentiated by RBBP6 
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siRNA transfection. A combination of chemotherapy with paclitaxel or camptothecin and 
RBBP6 siRNA could be a possible therapeutic strategy in combatting ovarian carcinomas. 
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CHAPTER ONE- INTRODUCTION AND LITERATURE REVIEW 
 
Introduction 
 
This chapter focuses on a review of literature in ovarian cancer. It covers the epidemiology, 
causes and risk factors of the disease. Mechanisms of apoptosis in ovarian cancer are also 
reviewed.  Current targeted therapeutic strategies using tyrosine kinase inhibitors and 
monoclonal antibodies are explored herein. RBBP6 is a 250kD protein shown to be 
upregulated in numerous cancers. We take a closer look at RBBP6 and its interaction with 
MDM2 to mediate p53 degradation. We review paclitaxel and camptothecin as current 
chemotherapy in ovarian cancer. Finally, we appraise a novel form of targeted therapy: 
siRNA technology and some advantages over other therapeutic strategies in ovarian cancer. 
This research applies a combination therapeutic strategy of RBBP6 siRNA transfection and 
paclitaxel or camptothecin in ovarian cancer; and is the first study carried out in this regard. 
 
1.1 Ovarian cancer overview 
 
Ovarian cancer is the leading cause of death among all gynaecological cancers in western 
countries. When compared to other gynaecological cancers, the mortality rate of ovarian 
cancer surpasses that of cervical and endometrial cancers put together (Jemal et al., 2008). 
This high death rate is due to the diagnosis at an advanced stage in most patients caused by 
the relative lack of specific signs and symptoms of the disease and the lack of reliable tests 
for early detection. Ovarian cancer is a highly metastatic disease characterized by widespread 
peritoneal dissemination and ascites and is the leading cause of death from gynaecologic 
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malignancies (Zhang et al., 2009; Gavalas et al., 2011; Kim et al., 2012). Despite aggressive 
surgery and platinum-based chemotherapy for patients presenting with clinically advanced 
ovarian cancer, the global five-year survival rate is only 15-20% (Parkin et al., 2008). 
Disease-associated mortality in ovarian carcinomas is most often as a result of metastasis. At 
the time of diagnosis, in most cases, disease has spread beyond the ovaries (Cannistra, 2004; 
Smith and Guidozzi, 2009). However, survival rates can be as high as 90% in stage I ovarian 
cancers (American Cancer Society, 2014) 
 
 
 
Figure 1.1: Relative 5-year survival for invasive epithelial ovarian cancer by stage. 
Adapted from: “Survival rates for ovarian cancer”. American Cancer Society, 2015.  
 
There are more than 30 types and subtypes of ovarian cancer; classified into 3 major 
categories according to the primary cells from which they arise. They are categorized as: 
epithelial tumours, stromal tumours and germ cell tumours (Kaku et al., 2003). Epithelial 
ovarian tumours (ovarian carcinomas) are the most prevalent and the most aggressive; 
accounting for about 90% of all ovarian cancers (Sankaranarayanan, 2006; Gavalas et al., 
2011).  
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1.2 Causes and Risk factors 
 
The exact cause of ovarian cancer is not known. However, there are several factors which can 
increase a woman’s risk of developing ovarian carcinomas. Regardless of the fact that 
molecular mechanisms of neoplastic transformation are inadequately understood, a handful of 
hypotheses have been put forward to explain the etiology of ovarian carcinomas (Zhang et 
al., 2009). The most popular of which are: the incessant ovulation theory (Fathalla, 1971) and 
the gonadotropin hypothesis (Ohtani et al., 2001). Not much is known about the causes and 
risk factors of stromal and germ cell ovarian tumours (American Cancer Society, 2015). 
 
1.2.1 The gonadotropin hypothesis  
 
This proposes that elevated serum gonadotropin levels (FSH and LH) play an important role 
in the development of epithelial ovarian cancers (EOCs) (Ohtani et al., 2001). This supports 
the observation that EOCs are most frequently diagnosed in postmenopausal women, with the 
median age of women affected being over 60 years, who usually show high serum 
gonadotropins levels (Cannistra, 2004). In addition, numerous studies on the risk factors and 
epidemiology of EOCs associate a decreasing risk of EOCs with length of lactation, 
increasing number of pregnancies (multiparity) and use of oral contraceptives (Schildkraut 
and Thompson, 1988; Gwinn et al., 1990); which are all typical of either lower levels of 
gonadotropins or decreased expression of their receptors (Daly and Obrams, 1998; Gnagy et 
al., 2000; La Vecchia, 2001). 
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1.2.2 The incessant ovulation theory  
 
It proposes that frequent ovulation-induced rupture of the OSE ensued by mitotic repair, 
without pregnancy-induced rest periods, is a possible cause of EOCs (Fathalla, 1971). This 
theory proposes that repeated bouts of apoptosis and mitotic restoration of cells of the ovarian 
surface epithelium (OSE) predisposes them to genetic mutations and genomic instability 
which usually herald the onset of neoplastic transformation. Factors that protect against EOC 
such as oral contraceptive use, lactation and pregnancy which characterise anovuation are in 
agreement with this theory. Additionally, risk factors such as nulliparity and usage of 
ovulation stimulating drugs (fertility treatment), all characteristic of incessant ovulation also 
give credence to this theory (Cannistra, 2004). In 2001, Murdoch and his colleagues showed 
a high degree of oxidative DNA damage on OSE cells of sheep around the site of ovulation. 
They suggested that in case the DNA damage goes unrepaired the cell may evade apoptosis, 
resulting to the emergence of a transformed progenitor cell which may become propagated 
during mitogenic repair of the OSE post ovulation (Murdock et al., 2001). 
 
1.3 Genetic risk factors 
 
Studies have indicated that the most predominant risk factor for ovarian cancer is having a 
strong family history of breast cancer, ovarian cancer or both (Cannistra, 2004). The most 
important risk factor associated with ovarian cancer is genetic mutations in the breast cancer 
DNA repair genes BRCA1 and/or BRCA2 genes which are prevalent in families with a 
history of breast and/or ovarian cancer (Cannistra, 2004). BRCA1 mutations represent a 30-
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40% chance of having the disease while BRCA2 mutations show a 10-15% lifetime risk 
(Antoniou et al., 2003). Some ethnic (Ashkenazi Jewish) groups show an increased frequency 
of germline BRCA1 and/or 2 mutations and show increased ovarian cancer incidence. In 
South Africa, germline BRCA mutations are the most common hereditary causes of ovarian 
cancer and affect about 1 in 500 women (Smith and Guidozzi, 2009).  Lynch syndrome (also 
called hereditary non-polyposis colorectal cancer (HNPCC)) is a mismatch repair germline 
mutation that predisposes individuals to certain types of cancer including colorectal, 
endometrial and ovarian cancers.  About 10 to 15% of hereditary cases of ovarian cancer 
occur in women having Lynch syndrome (Rubin et al., 1998).  
Milder, less aggressive and genetically more stable ovarian cancers involve mutations of 
KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue), BRAF (v-Raf murine 
sarcoma viral oncogene homolog B1), PTEN (Phosphatase and tensin homolog) and B-
catenin, mostly termed borderline tumours. A majority of sporadic mutations in EOC are as a 
result of mutations in the p53 and retinoblastoma tumour-suppressor pathways (Sherr and Mc 
Commick, 2002). Most high grade epithelial ovarian cancers (carcinomas) are as a result of 
TP53 mutations with examples such as undifferentiated tumours, high grade serous 
carcinomas and mixed malignant mesodermal tumours (Kurman and Shih, 2008).  About 
50% of human cancers have shown inactivation of p53 through mutations or loss. In most 
characterized tumours retaining wild type p53, disruptions have been found in the p53 
pathway of tumour suppression (Harris and Hollstein, 1993). Mutations in p53 gene are 
frequently encountered in ovarian cancer (Kupryjanczyk et al., 2000). It seems reasonable to 
make use of therapeutic strategies that target the p53 pathway of tumour suppression.  
Lifestyle factors such as cigarette smoking, alcohol consumption, poor diet and sedentary 
habits have been associated to increased risk of developing the disease (Anand et al., 2008). 
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1.4 Epidemiology 
 
According to estimates from the International Agency for Research on Cancer (IARC), 
cancer is a leading cause of death worldwide with an estimated 7.6 million deaths in 2008 
(approximately 21,000 deaths per day) (American Cancer Society, 2008). Ovarian cancer has 
taken its toll on health worldwide with approximately 239,000 cases diagnosed in 2012, 
claiming about 152, 000 lives (Cancer Research, UK, 2014). Cancer has received less 
focused attention in Africa partly as a result of the immense burden of infectious or 
communicable diseases such as HIV/AIDS and malaria because more resources are being 
directed to curb infectious diseases (Parkin et al., 2008). Survival rates of cancer are even 
worse in developing countries because of later diagnosis due to poorer screening facilities. 
Public health providers have a limited knowledge of signs and symptoms at early stages of 
cancer, and patients have limited access to prompt and standard treatment (WHO, 2002). 
Most tellingly, the statistics of cancer in Africa, showing high rates of incidence, morbidity 
and mortality, emphasize the severity of the problem. Incidence rates of about 4.2 per 
100,000 of the population were recorded in ovarian cancer in 2008. The corresponding 
mortality was as high as 3.4 women per 100,000 (GLOBOCAN, 2008). 
Cancer generally results when mechanisms that control apoptosis are dysfunctional.  
For us to be able to properly comprehend pathological apoptosis in the human ovary, it is 
imperative that we have a grasp of the underlying principles of physiological apoptotic 
processes in the ovary.  
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1.5 Apoptosis as cell division guardian 
 
Therapies that are currently used in cancer treatment such as chemotherapy, radiotherapy and 
a handful of targeted therapeutic approaches exert their effects by inducing programmed cell 
death or apoptosis (Fulda and Debatin, 2006). It is therefore pertinent for us to understand 
apoptosis, the mechanisms responsible for it, its regulation and dysfunction in health and 
disease. 
Apoptosis is a programmed mode of physiological cell death that is genetically controlled, 
tightly regulated and evolutionarily conserved. It functions in regulating cell populations in 
embryogenesis, cellular homeostasis, metamorphosis and defence (Kerr et al., 1972; 
Metzstein et al., 1998; Gupta, 2001; Renehan et al., 2001). It has been shown that both 
physiological and pathological stimuli can initiate or inhibit apoptosis. They include 
oncogenic activation, DNA damaging cytotoxic drugs, irradiation, ligation of death receptors, 
and lack of growth factors or survival signals (Renehan et al., 2001). Apoptosis is generally 
morphologically characterised by rapid cytoplasmic and chromatin condensation, 
internucleosomal DNA fragmentation and cell fragmentation. Protuberances then form on the 
cell membrane and are later budded-off to form membrane-bound structures. The membrane-
bound bodies are then phagocytosed (Kerr et al., 1972; Walker et al., 1987). Necrosis, unlike 
apoptosis is pathological and traumatic form of cell death resulting in cellular inflammation 
and rupture Cell death by necrosis is usually as a result of external injury while apoptosis is 
as a result of internal or external insults that lead to programmed cell suicide (Schwartz et al., 
1990). 
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1.5.1 Apoptotic pathways 
 
Two main pathways of apoptosis have been elucidated: The death receptor (extrinsic) 
pathway and the mitochondrial (intrinsic) pathway of apoptosis. The extrinsic pathway of 
apoptosis involves binding of ligands to cell surface receptors of the tumour necrosis factor-
alpha (TNF-α) superfamily. The death receptor-ligand binding leads to transmission of the 
death signal through death domains, death effector domains and caspases recruitment 
domains. The caspase recruitment domains cause the activation of procaspases and adaptor 
proteins. Procaspases are then cleaved to form active caspases which lead to apoptosis 
(Hussein, 2005).  The intrinsic pathway is regulated by members of the Bcl-2 family. Upon 
reception of a death signal such as ultra violet rays, gamma radiation oncogenic activation or 
chemotherapeutic agents by the cell, p53 becomes activated. Depending on the cellular 
context, activated p53 transcriptionally activates a combination of many pro-apoptotic genes 
such as Bax, Bak, Bad and BH3-only proteins (NOXA and PUMA), growth arrest gene p21, 
DR5, Bid, Fas and a host of others (Wu et al., 1997; Oda et al., 2000; Nakano and Vousden, 
2001; Sax et al., 2002;). P53 has also been shown to repress the activity of anti-apoptotic 
genes such as BCl2 (Spierings et al., 2005; Vousden and Prives, 2009). Pro-apoptotic 
members of the Bcl-2 family are stimulated to formation of pores on the mitochondrial 
membrane enabling the release of cytochrome c out of mitochondria into the cytoplasm 
(Hussein et al., 2003a). Cytochrome c will then bind to Apaf 1, alongside dATP to form the 
apoptosome complex (Gewies, 2003; Spierings et al., 2005). The apoptosome complex will 
cleave and activate caspase 9, which in turn activates a cascade of events involving 
executioner caspases resulting in apoptosis (Gupta, 2001; Spierings et al., 2005).  A p53-
mediated transcriptional upregulation of DR5 (Wu et al., 1997) and Fas (Muller et al., 1998) 
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leads to apoptosis via the death receptor pathway. This describes a cross-talk that exists 
between intrinsic and extrinsic apoptotic pathways.   
 
1.5.2 Cell cycle regulation and p21 
 
We evaluated the expression of a cell cycle regulatory gene, p21 in this study. The p21 gene 
is a growth arrest gene that is transactivated by elevated p53 in response to various stress 
signals (Waldman et al., 1995; Sherr and Roberts, 1995), although it can also be activated by 
p53-independent mechanisms (Johnson et al., 1994; Kibbe et al., 2000). P21 protein induces 
G1 cell cycle arrest by inhibiting the activity of CDKs, blocking their ability to phosphorylate 
Rb and hence inhibiting the transcription of early S-phase genes by E2F (Chen et al., 1998.)  
 
1.5.3 Regulation and failure of apoptosis 
 
The intricacy of apoptotic regulation can be justified by an ever-expanding list of proteins 
and genes that are involved in the process. The pro-apoptotic and antiapoptotic BCl2 family 
of proteins which have been extensively studied are primarily responsible for the regulation 
of apoptosis. In a viable cell, the effects of pro-apoptotic members such as Bax and Bad are 
counterbalanced by those of pro-survival members such as BCl2 and BclX (Gewies, 2003). 
Another group of proteins known as inhibitors of apoptosis (IAP) inhibit apoptosis by 
blocking the activity of caspases. However, the effects of IAP are neutralised by Smac, a 
protein which is released from the mitochondria. During ovarian follicular development, X-
linked IAP expression is increased. It facilitates the development of follicles by FSH and also 
inhibits the apoptosis of follicular cells (Hussein, 2005). 
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There is a fine-tuned balance between the number of cells that are produced by mitosis and 
those that die via apoptosis in a healthy living organism. Millions of cells are produced in a 
day by cell division, while a similar number dies by apoptosis. However, this balance 
between cell division and apoptosis becomes compromised in numerous diseased states. 
Excessive apoptosis contribute to neurodegenerative diseases (Parkinson’s disease, 
Alzheimer’s disease and Huntington’s disease) while insufficient apoptosis may lead to 
autoimmunity and cancer (Reed, 2002). Dysregulation of apoptosis is usually as a result of 
genetic mutations or epigenetic modifications and is particularly very important in cancer. 
This study seeks to improve upon apoptosis by RBBP6 gene knockdown and paclitaxel and 
camptothecin treatments a therapeutic strategy in ovarian cancer. 
 
1.5.4 Role of apoptosis in ovarian follicle development and maintenance 
 
 The ovary provides a paradigm for programmed cell death due to the cyclic nature of ovarian 
development and function (Hussein, 2005). Apoptosis is critical for ovarian function, bearing 
in mind that it regulates the cyclical processes in the female reproductive system. Apoptosis 
has been shown to be the underlying mechanism of cell death in the ovaries. It has been 
observed in germ cell loss (germ cell attrition), follicular atresia and corpus luteum regression 
(luteolysis) and ovarian surface epithelial cells prior to ovulation (Murdoch et al., 1995, 
Murdoch et al., 2002; Tilly, 1996; Hussein, 2005). 
  Follicular atresia: Follicular atresisa is the breakdown and resorption of ovarian follicles 
which occurs prior to ovulation (Santos et al., 2008). Several studies have shown that 
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apoptosis of granulosa cells is the main mode of cell death in follicular atresia (Tilly et al., 
1991; Kaipia and Hsueh, 1997; Manabe et al., 2008). 
Luteolysis: Luteolysis is the degeneration of the corpus luteum which occurs at the end of the 
female reproductive cycle in the absence of pregnancy (Vaskivuo and Taipanainen, 2003). 
The molecular effectors that have been shown to be mediators of luteolysis include Fas/Fas 
ligand, prostaglandin F2-α, endothelins, integrins, interferon-γ, (Moeljono et al., 1977; Quirk 
et al., 1995; Otani et al., 1996; Petroff et al., 2001; Wall et al., 2003). 
Apoptosis in germ cell attrition:  About seven million oocytes are produced in the ovary 
during the early life of the human foetus. However, there is a drastic reduction of the number 
of oocytes, to about one third, by apoptosis, shortly after birth (Manabe et al., 2008).  Defects 
in apoptosis or sustained proliferation of germ cells may lead to germ cell tumours of the 
ovary. 
1.6 Apoptosis in ovarian cancer and its therapeutic targets 
 
In the last decades, basic cancer research has produced remarkable advances in our 
understanding of cancer biology and cancer genetics. Among the most important of these 
advances is the realization that apoptosis and the genes that control it have a profound effect 
on the malignant phenotype. For example, it is now clear that some oncogenic mutations 
disrupt apoptosis, leading to tumour initiation, progression or metastasis (Motadi et al., 2011; 
Chen et al., 2013). It is now well documented that most cytotoxic anticancer agents induce 
apoptosis, raising the possibility that defects in apoptotic mechanisms contribute to treatment 
failure (Lowe et al., 2000). Since apoptotic programs can be manipulated to produce massive 
changes in cell death, the genes and proteins controlling apoptosis are potential drug targets. 
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Recently, most anticancer agents now in use were developed with the sole purpose of 
inducing apoptosis that will selectively kill tumuor cells. So, targeting apoptosis remains the 
main focus and safest route towards combating cancer. 
 
1.6.1 Targeted therapy in Ovarian Cancer 
 
Despite optimal chemotherapeutic and surgical treatment of ovarian cancer patients 
presenting with advanced disease, 10 to 15% show long-term subsidence. More than 70% of 
chemotherapeutically treated ovarian cancer cases show resistance, and subsequent relapse to 
platinum-based drugs and paclitaxel (Copeland et al., 1994; Bartel et al., 2008; Gavalas et al., 
2011). This necessitates research into alternative therapeutic strategies against ovarian cancer.  
Conventional cancer chemotherapy is cytotoxic, and indiscriminately targets rapidly-dividing 
cells of the body. In a bid to destroy cancerous cells, some normal body cells are killed in the 
process, resulting in serious side effects (American Cancer Society, 2006). Damages to hair 
follicular cells, bone marrow cells, gastro-intestinal cells and cells lining the reproductive 
tract account for a great proportion of side effects experienced by chemotherapeutic use. 
Also, additional limitations of traditional chemotherapy include the palliative and 
unpredictable responses produced by patients (Arora and Scholar, 2005). 
However, targeted therapy depicts a new generation of anti-cancer therapeutics that are 
designed  to ideally interact with a specific molecule, usually a protein molecule, that is 
believed or shown to have a vital role in tumour progression or growth  (Wu et al., 2006; 
Arora and Scholar, 2005).   
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Researchers (Ross et al., 2004) have proposed a set of criteria that qualify an ideal molecular 
target in cancer therapy. They include the following:  
i) The molecule should be significantly expressed in vital tissues.  
ii) It should be reproducibly measured in clinical samples. 
iii)  It should correlate with clinical outcome; yielding a clinical response in a significant amount 
of patients whose tumours expresses the target, and shows a trivial response in those whose 
tumours don not express the target. (Ross et al., 2004). 
However, side effects have been reported in numerous clinical trials involving small 
molecule tyrosine kinase inhibitors some of which are as a result of unintended targets.  They 
include fatigue, bowel perforations and severe diarrhoea,  hypertension, hand-foot syndrome 
and proteinuria as observed in some vascular endothelial growth factor receptor (VEGFR) 
and epidermal growth factor receptor (EGFR) inhibitors (Friedlander et al., 2007; Azad et al., 
2008; Nimeiri et al., 2008; Biagi et al., 2008). 
As opposed to conventional chemotherapy, a hallmark of the action of targeted cancer 
therapeutics is a higher degree of selective toxicity. This aspect of an anticancer drug may be 
improved upon by either augmenting the concentration of the therapeutic agent that reaches 
the tumour tissue or decreasing the amount that reaches normal tissues (Singh et al., 2010). 
However, synergistic anticancer effects have been achieved by using targeted therapeutic 
approaches in combination with cytotoxic chemotherapy (Aurora and Scholar, 2005). 
Various targeted therapeutic strategies have been explored in ovarian cancer management, 
often used in combination with chemotherapeutic agents for maximal results. Targeted cancer 
therapeutics can be grouped into two broad categories: kinase inhibitors and monoclonal 
antibodies (Wu et al., 2006; Aurora and Scholar, 2005).  
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1.6.2 Tyrosine Kinases  
 
Tyrosine kinases are molecules that play crucial roles in signal transduction, culminating 
their effects by regulating gene transcription within the nucleus. They function by 
transferring γ-phosphate groups from adenosine triphosphate to the hydroxyl group of protein 
molecules responsible for signal transduction (Schlessinger, 2000). A major event that 
activates tumour proliferation is the phosphorylation of signal transduction molecules. The 
most essential cellular processes such as the cell cycle, cell division, differentiation, motility 
and apoptosis or cell survival are under scrupulous regulation of tyrosine kinases (Prenzel et 
al., 2001; Slichenmyer and Fry, 2001). Dysfunctions in tyrosine kinases pre-dispose signal 
transduction molecules to sustained phosphorylation hence abnormal cell proliferation. 
Tyrosine kinases have been found over-expressed or mutated in several types of tumours in 
humans including ovarian tumours (Levitzki and Gazit, 1995; Blume-Jensen and Hunter, 
2001; Wiener et al., 2003) making them good targets for cancer therapy.  
 Small molecules have been developed to target tyrosine kinases while monoclonal antibodies 
target surface proteins or antigens that are differentially expressed, overexpressed or mutated 
in cancer cells compared to normal tissues. Monoclonal antibodies function by inducing 
changes in the function of the antigen or receptor in question such as invoking an immune 
response, or conjugating a drug to the antibody which targets a specific antigen (Scott et al., 
2007). 
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1.7 Molecular therapeutic targets in ovarian cancer  
1.7.1 Angiogenesis inhibitors 
 
One of the key features leading to metastasis and invasion of normal tissues by cancerous 
cells is angiogenesis (the formation of new blood vessels). Poor prognosis in ovarian cancer 
has been confirmed to be associated with increased expression of the vascular endothelial 
growth factor (VEGF) which has functions such as angiogenesis, mitogenesis, improvement 
of vascular permeability, and endothelial cell survival (Folkman, 1997; Hartenbach et al., 
1997).  Small molecule tyrosine kinase inhibitors have been developed to target the VEGF 
ligand and the VEGF receptor in ovarian cancer thereby slowing angiogenesis and improving 
upon prognosis of disease (Friedlander et al., 2007; Campos et al., 2008; Hirte et al., 2008; 
Becker et al., 2013). 
 
1.7.2 Inhibitors of the epidermal growth factor receptor (EGFR) 
 
EGFR is a transmembrane tyrosine kinase protein receptor that is involved in cell 
proliferation, survival and differentiation (Herbst, 2004). About 70% of ovarian cancers show 
upregulated expression in EGFR, making it an attractive target for the treatment of ovarian 
carcinomas. Over-expression of EGFR has been shown to correlate with chemoresistance and 
poor prognosis. Increased cell proliferation, angiogenesis and reduced apoptosis are attributed 
to over-expression of EGFR (Bartlett et al., 1996, Fischer-Colbrie et al., 1997).Tyrosine 
kinase inhibitors such as erlonitib and gefitinib have been successfully directed against the 
EGFR (Sirotnak et al., 2000; Sirotnak, 2003). Phase 2 clinical trials with gefinitib in patients 
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with advanced recurrent ovarian carcinomas showed very little activity, although the drug 
was well tolerated (Schilder et al., 2005). Phase 3 trials with erlonitib, however did not show 
any significant improvement in activity (Vergote et al., 2013). 
 
1.7.3 Aurora kinase inhibitors 
 
Aurora A is a serine-threonine kinase that is required for many essential cellular functions 
such as mitosis, spindle formation and centromere separation (Bischoff et al., 1998; Campos 
and Gosh, 2010). An over-expression of Aurora A as well as amplification of its gene 
location have been frequently noted in human tumours, including in ovarian carcinomas 
(Bischoff et al., 1998; Zhou et al., 1998; Lingle et al., 1998; Landen et al., 2007). Aurora A 
has been shown to inhibit paclitaxel and cisplatin –mediated apoptosis in ovarian cancer cells 
(Yang et al., 2006; Anand et al., 2003).  Aurora kinase inhibition with a small molecule MK-
0457 in combination with chemotherapy (docetaxel) has shown significant reduction in 
tumour growth and cell proliferation in HeyA8 and SKOV3ip1 ovarian cancer cell lines (Sun 
et al., 2007; Lin et al., 2008; Traynor et al., 2011). 
 
1.7.4 Poly ADP Ribose Polymerase (PARP) inhibitors 
 
BRCA1 and BRCA2 play an important role in DNA double strand break repairs and 
maintaining genomic stability (Lord and Ashworth, 2008). BRCA ovarian cancer patients 
show an impaired ability to repair damaged DNA. Mutations in these genes account for 5 to 
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10% of all ovarian cases. BRCA genes represent the most important risk factor in ovarian 
cancer with lifetime risks of between 40-50% and 10-20% for BRCA1 and BRCA2 
respectively (Cannistra, 2004; Lord and Ashworth, 2008). More than 50% of high grade 
serous ovarian carcinomas show loss of function of BRCA genes, either by genetic or 
epigenetic causes (Press et al., 2008). Poly ADP Ribose Polymerase (PARP) is a nuclear 
enzyme involved in the DNA single strand break repair (Tutt et al., 2005). It is activated in 
DNA damage and its inhibition results in DNA single strand breaks which may result in 
double strand breaks. BRCA1 and BRCA 2 patients show high sensitivity to DNA-damaging 
chemotherapeutics and have also shown immense responsiveness to PARP inhibitors (Bryant 
et al., 2005; Tutt et al., 2005). Although the mechanism is not fully understood, Lord and 
Ashworth (2008) suggest that an excessive amount of DNA single strand breaks with 
subsequent double strand breaks leads to high irreparable genomic instability and hence, cell 
death.  Olaparib is a small molecule PARP inhibitor that has been used and has shown 
efficacy in BRCA1 ovarian cancer patients and has It has passed the first phase of clinical 
trials (Fong et al., 2008). 
 
1.7.5 Platelet-derived growth factor (PDGF) receptor inhibitors 
 
PDGF is involved in cellular growth, survival, differentiation, vascular permeability, cellular 
migration and healing of wounds (Schmitt and Matei, 2008). Between 50% and 80% of 
ovarian cancers show activation of the PDGF receptor which is involved in neoplastic 
transformation (Heinrich et al., 2003; Apte et al., 2004). PDGF receptor activation is as a 
result of mutations, genetic amplification or chromosomal rearrangements (Carroll et al., 
1996; Heinrich et al., 2003). Imatinib mesylate (STI57) is a small molecule that has been 
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used to target PDGF receptor. A significant induction of apoptosis and reduction in tumour 
weight was observed in this study when STI571 was used in combination with paclitaxel.  
However, STI571 alone did not cause any significant effects (Apte et al., 2004). Imatinib is a 
small molecule PDGF receptor inhibitor that has passed phase two clinical trials in ovarian 
cancer patients whose tumours express the PDGF receptor (Alberts et al., 2007). 
 
1.7.6 MTOR inhibitors 
 
PTEN is a lipid phosphatase that is involved in G1 cell cycle arrest and apoptosis through the 
AKT /PI3K /mTOR pathway and has been shown to be mutated, deleted or inactivated in 
gynaecologic tumours (Sansal and Sellers, 2004; Jiang and Liu, 2008; Campos and Gosh 
2009). The mTOR pathway is a key regulator of cell growth, proliferation and programmed 
cell death (Campos and Gosh 2009). Inhibitors of mTOR such as everolimus (RAD001) have 
been shown to inhibit angiogenesis, tumour proliferation and ascites formation in vivo and in 
vitro using OVCA10 and SKOV-3 ovarian cancer cells. It also improved upon cisplatin-
mediated apoptosis These suggest a promising role of mTOR inhibitors to treat ovarian 
tumours (Gera et al., 2004; Mabuchi et al., 2007; Okamoto et al., 2010). 
 
1.7.7 Targeting Bcl-2 Family in ovarian cancer and apoptosis 
 
Bcl-2 family of proteins is divided into two types of proteins ones that can induce apoptosis 
referred to as pro-apoptotic and those that inhibit apoptosis called antiapoptotic molecules. 
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The most common protein which is well defined is Bcl-2 which is an antiapoptotic molecule 
that exerts its effects by binding to Bax, blocking c-Myc-induced apoptosis, blocking 
mitochondrial release of cytochrome-C and also inhibiting Apaf-1 interaction with Caspase-9 
(Luo et al., 1997).  In the ovaries, Bcl-2 is expressed mainly in healthy ovarian follicles while 
Bax, a pro-apoptotic molecule which is a pro-apoptotic molecule, is expressed in the follicles 
undergoing atresia. Bcl2 and Bax expression are markedly influenced by gonadotrophin 
levels. Elevated gonadotrophins tend to inhibit Bax expression while increasing Bcl-2 and 
Bcl-xL expression, hence promoting the survival of the follicle (Tilly et al., 1995a; Sugino et 
al., 2000).  Tilly et al (1995a) analyzing the expression of Bcl2 family of protein in the 
immature ovaries of a rat during follicular atresia found the correlation between Bax mRNA 
which was upregulated and that of Bcl2 and Bcl-xL down-regulated. Other pro-apoptotic 
molecules such as Mcl-1, Bax and Bok elicit their apoptotic effects by triggering 
mitochondrial cytochrome-c release. Cytochrome c binds to Apaf-1, forming the apoptosome 
and activating the caspase cascade which leads to apoptotic cell demise (Tilly et al., 1995b).   
Because of the importance of these pro- and anti-apoptotic proteins in deciding if the cell 
undergoes apoptosis or they survive, they have become a target for many researchers who are 
eager to restore apoptosis in cancer cells. Ovarian cancer is mainly associated with mutations 
in some of the genes that might trigger apoptosis and restoring their functions might be 
alternative therapeutic options. In recent years several small molecules that aimed to target 
Bcl-2 thereby inhibiting its activity in cancer cells are identified as possible therapeutic 
option. One of the recently discovered molecules that act as a selective inhibitor of Bcl2 is 
AB-737 and its orally active product AB-263where shown to inhibit cell growth in eight 
different ovarian cancer cell lines, although with relatively poor potency. Further test 
revealed that ABT-737 increased the sensitivity of several cell lines to carboplatin when 
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ABT-737 was administered after carboplatin (Witham et al., 2007; Jain et al., 2014). In 
addition, ABT-737 significantly enhanced the activity of carboplatin in one of three primary 
cultures derived directly from ascitic tumour cells in patients recently treated with 
chemotherapy. The increased sensitivity to carboplatin was accompanied by a decrease in 
time at which apoptosis was observed when assessed according to the number of attached 
cells, PARP cleavage, and nucleosome formation (Witham et al., 2007). When carboplatin 
was co-administered with Small interfering RNA directed to Bcl-xL or BCl2 IGROV-1 
tumour xenograft growth was highly inhibited as compared to treatment with carboplatin 
(Witham et al 2007). In recent clinical trials, ABT-737 is able to prolong the survival of 
recipient mice transplanted with Bcl-2-transduced tumours. It was also found to be functional 
with co-treatment with chemotherapy. 
 
1.7.8 Minimizing expression of Inhibitors of Apoptosis (IAP) as target for 
ovarian cancer 
 
The inhibitor of apoptosis proteins (IAPs) constitutes a family of highly conserved apoptosis 
suppressor proteins that were originally identified in baculoviruses. Although IAP homologs 
have recently been demonstrated to suppress apoptosis in mammalian cells, their expression 
and role in human ovarian epithelial cancer and chemotherapy resistance are still unknown or 
not clear. To date eight IAPs have been identified, namely, NAIP (BIRC1), c-IAP1 (BIRC2), 
c-IAP2 (BIRC3), X-linked IAP (XIAP, BIRC4), Survivin (BIRC5), Apollon (BRUCE, 
BIRC6), Livin/ML-IAP (BIRC7) and IAP-like protein 2 (BIRC8)  (Vucic and Fairbrother, 
2007 ). IAPs are endogenous inhibitors of caspases and they can inhibit caspase activity by 
binding their conserved BIR domains to the active sites of caspases, by promoting 
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degradation of active caspases or by keeping the caspases away from their substrates (Wei et 
al 2008). Dysregulated IAP expression has been reported in many cancers.  For example, 
Lopes et al demonstrated abnormal expression of the IAP family in pancreatic cancer cells 
and that this abnormal expression was also responsible for resistance to chemotherapy.  So 
far, XIAP has been reported to be the most potent inhibitor of apoptosis among all the IAPs 
(Svane et al, 2004). It effectively inhibits the intrinsic as well as extrinsic pathways of 
apoptosis and it does so by binding and inhibiting upstream caspase-9 and the downstream 
caspases-3 and -7 (Svane et al., 2004).  
When designing novel drugs for cancers, the IAPs are attractive molecular targets. In normal 
ovaries, surging FSH in the ovary upregulates XIAP which leads to a suppression of 
granulosa cell apoptosis and promotes the growth of follicles, induced by FSH (Hussein, 
2005; Xiao et al., 2001; Scott et al., 2005). It also said to effectively inhibits the intrinsic as 
well as extrinsic pathways of apoptosis and it does so by binding and inhibiting upstream 
caspase-9 and the downstream caspases-3 and -7 (Hussein, 2005; Xiao et al., 2001; Scott et 
al., 2005). So, if this is true even during ovarian cancer development, XIAP might provide 
much better molecular therapeutic target in chemo-resistant ovarian cancer. In recent years, 
some novel therapy targeting XIAP included antisense strategies and short interfering RNA 
(siRNA) molecules.  In their using the antisense approach, Dai et al (2009) reported 
inhibition of XIAP resulted in an improved in vivo tumour control by radiotherapy. In another 
study by Li et al (2001), it was shown through the use of cisplatin-sensitive and -resistant 
human ovarian surface epithelial (hOSE) cancer cell lines and adenoviral antisense and sense 
complementary DNA expression to examine the role of IAP in the regulation of apoptosis in 
human ovarian cancer cells and chemoresistance that Cisplatin consistently decreased XIAP 
content and induced apoptosis in the cisplatin-sensitive, but not cisplatin-resistant cells.  
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1.7.9 Therapuetical potential of TNF family members 
 
Tumor necrosis factor alpha (TNF-α), also known as cachectin and TNFSF2, is the prototypic 
ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in 
inflammation, apoptosis, and immune system development.   In normal ovarian development, 
the expression of some TNF family members such as FasL/Fas is highly influenced by 
gonadotrophin levels. Surging gonadotrophin levels result to a decreased expression of 
Fas/FasL, thereby promoting follicular survival. However, decreased gonadotropin levels 
result in an increased expression of Fas/FasL, leading to follicular atresia (Jiang et al., 2003).  
TNF-α is abundant in the ovarian cancer microenvironment. TNF-α modulates the expression 
of CD44 in normal T lymphocytes and CD44 is implicated in ovarian carcinogenesis and 
metastases (Muthukumaran et al., 2006).  TNF family members show both pro-survival and 
pro-apoptotic functions, depending on the type of receptors that are activated.  TNF- α 
triggers apoptosis by activating caspases (Wang et al., 2008); on the other hand, TNF-α is 
able to aid the survival of granulosa cells by upregulating the expression of  and XIAP 
through the NFκB system (Jiang et al., 2003).  TRAIL is another TNF family member that 
has been shown to induce apoptosis in tumour cells, but not in normal cells, owing to the 
presence of TRAIL decoy receptors which competitively inhibit the binding of TRAIL 
ligands to their cognate receptors (Sheridan et al., 1997; Pan et al., 1997).  TRAIL and its 
receptors are expressed in growing, atretic and antral ovarian follicles (Bobe and Goetz, 
2001).  
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1.7.10 Wild-type p53: the genomic guardian target 
 
This gene encodes a tumour suppressor protein containing transcriptional activation, DNA 
binding, and oligomerization domains. The encoded protein responds to diverse cellular 
stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, 
senescence, DNA repair, or changes in metabolism. Scientists have dubbed p53 “the guardian 
of the genome” (Levine, 1997) and “the cellular gate-keeper” (1992) because of its critical 
function in regulating responses to a wide range of cellular stress factors.  P53 
transcriptionally activates apoptotic and growth arrest genes and also represses pro-survival 
genes (C-myc repression (Ho et al., 2005), Bcl2 repression (Miyashita et al., 1994; Wu et al., 
2001)). The response of p53 to cellular stresses is dependent on the type and duration of 
stress or extent of DNA damage and cellular growth conditions. P53 induces the transcription 
of target genes which can either lead to apoptosis, growth arrest to enable DNA repair, 
senescence or cellular differentiation (Hupp et al., 1992). P53 has a very short half-life, and 
becomes rapidly degraded in normal physiological conditions.  
 
1.7.11 Regulation of p53 
 
MDM2 is a multi-domain oncoprotein that is encoded by the MDM2 gene. It has an N-
terminal domain that contains the binding sites of p53 and p73; a putative ZINC finger 
domain that binds the Rb protein; an acidic domain which contains the p14 binding site; and a 
p53 ubiquitination site, which is a  RING finger E3 ligase domain (Momand et al., 2000). 
Under normal physiological conditions, p53 and MDM2 regulate the cellular levels of each 
other via their interactions in an auto-regulatory feedback loop. When p53 becomes activated, 
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it binds to the MDM2 P2 promoter and induces the expression of MDM2 protein. While 
activated p53 transcriptionally upregulates a handful of genes, including MDM2 (Picksley 
and Lane, 1993; Wu et al., 1993), MDM2 in turn represses the activity of p53 possibly via 
the following mechanisms: 
 The activity of MDM2 as an E3 ubiquitin ligase enables it to target p53 for 
degradation by the proteasome.  
 MDM2 inhibits p53 binding to DNA thereby preventing its functions as a 
transcription factor. This aspect is achieved by MDM2 binding to p53 and inducing its 
export out of the nucleus. 
 The binding of MDM2 to the p53 transactivation domain prevents p53 from carrying 
out it transcription activation functions 
(Chen et al., 1993; Oren et al., 1999; Tao and Levine, 1999; Honda and Yashuda, 2000) 
 
Upon DNA damage, p53 becomes activated or stabilised by phosphorylation (Karin and 
Hunter, 1995; Shieh et al., 1997), acetylation of the C-terminus (Gu and Roeder, 1997) and 
other mechanisms, depending on the cellular context.  Activated p53 translocates from the 
cytoplasm to the nucleus and acts in concert with other oncogenes and transcription factors to 
modulate cell proliferation by selectively activating a specific subset of proapoptotic and 
growth arrest genes, and repressing antiapoptotic genes. The mechanisms still remains 
unclear (Budhram-Mahadeo et al., 1999; Alarcon-Vargas and Ronai, 2002). 
The effects of p53 are mainly as a result of its activity as a transcription factor. It 
transcriptionally activates pro-apoptotic genes such as Bax, PUMA, NOXA and the growth 
arrest gene p21.  It represses the transcription of anti-apoptotic genes such as Bcl2 and Bcl-
Xl, MDM2 (Barak et al., 1994; Wu et al., 2001; Ohtani et al., 2004). p53 is expressed in 
25 
 
apoptotic granulosa cells of atretic follicles, suggesting a possible role of p53 in follicular 
atresia (Kim et al., 2000). One of the ways by which Gonadotropins inhibit apoptosis is by 
repressing a host of pro-apoptotic genes including p53 gene expression (Tilly et al., 1995b). 
APR-246 is converted to the active compound MQ that binds covalently to mutant p53, 
refolding it to wild type conformation2 and reactivating p53-dependent apoptosis (von Euler 
et al., 2014).  
 
1.7.12 Molecules targeting p53 
 
In targeting the reactivation of p53 in ovarian cancer, APR-246 was shown not only able to 
reactivates mutant p53, but also decreases intracellular glutathione levels in a dose-dependent 
manner (von Euler et al 2014). This unique mechanism of action, targeting both mutant p53 
and glutathione, is likely to account for the strong synergistic effects of APR-246 and 
platinum drugs as well as resensitization of ovarian cancer cells, which were observed in the 
study. Ad5CMV-p53 is a recombinant adenoviral vector that encodes TP53. The co-
administration of Ad5CMV-p53 intraperitoneally with chemotherapy using gemcitabine 
showed synergistic effects in the treatment of recurrent disease after multiple cycles of 
therapy (Wen et al., 2003). In another study, it was shown that Ad5CMVp53 showed a 
substantial clinical activity when used in combination with platinum-based chemotherapy to 
treat recurrent ovarian cancer (Buller et al 2002). Another molecule, CDB3, which is a 
synthetic p53 binding protein-derived peptide (53BP2), is known to interact with the core 
domain of p53 and upregulate the transactivation activity of p53 (Samuels-Lev et al 2001. A 
fluorescently tagged CDB3 was shown to improve the proper native folding of 
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p53Arg273His contact and p53Arg175His mutants; induce p53-mediated transactivation of 
p21, MDM2 and GADD45; and induce apoptosis. 
It was observed that, after treatment with CDB3 alone, apoptosis was not induced in wild-
type p53-bearing cells. Notwithstanding, the cells showed enhanced sensitivity to apoptosis 
induced by infra-red radiation (Weill et al., 2000). Cp-31398, a styrylquinazoline, is a small 
synthetic molecule that was identified for its ability to stabilize p53 against thermal 
denaturation in vitro. Treatment with Cp-31398 blocks the ubiquitination and degradation of 
p53 resulting in increased DR5 cell surface exposure and activation of the intrinsic 
bax/mitochondrial/caspase-9 pathway, culminating in apoptosis (Vecil et al., 2003). Because 
of the critical inhibitory role of MDM2 and RBBP6 on p53, blocking the interaction of 
RBBP6, MDM2 and p53 has been proposed as a potential cancer therapeutic strategy. Nutlin-
2 is a small-molecular-weight inhibitor that fits into the pocket where wild-type TP53 binds 
to MDM, a molecule required for the rapid degradation of TP53 through the ubiquitin-
proteasome pathway (Wang et al., 2012). Inhibition of the MDM–TP53 interaction results in 
the increased expression of wild-type TP53, inhibiting tumour growth and inducing 
apoptosis.  In a study by Moela et al., 2014, silencing breast cancer cell lines with RBBP6 
siRNA followed by treatment with camptothecin also sensitized cancer cells to apoptosis 
induced cell death which serves as a promising natural cell biology pathway. 
 
1.7.13 Other apoptotic molecular targets for ovarian cancer cells 
 
 Interferons (IFN): IFN-γ is a potent immunomodulatory, antiviral, and antiproliferative 
cytokine that has anticancer activity. IFN-γ directly inhibits human tumor cell growth and 
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induces apoptosis (Clemens, 2003). They include IFN-α, IFN-γ, IFN-β and IFN-δ. Interferons 
sensitize cells to apoptosis-inducing genes and proteins in apoptotic pathways (O’Connell et 
al., 2000; Lissat et al., 2007). IFN- δ inhibits Fas expression in the corpus luteum, thereby 
inducing apoptosis in bovine luteal cells (Komatsu et al., 2003). This is as a result of anti-
apoptotic Fas effects in the corpus luteum. IFN- γ has been shown to induce apoptosis in 
luteal cells and ovarian cancer cells both in vivo and in vitro (Petroff et al., 2001; Wall et al., 
2003). In ovarian cancer cell linea and xenografts in nude mice IFN was found to induce 
apoptosis and inhibit proliferation of cancer cell (Wall et al., 2003). IFN-γ might be a useful 
biological treatment of human epithelial ovarian cancer if sustained levels of this cytokine 
could be achieved within the peritoneum by improved protein or gene delivery strategies. 
 Integrins: are transmembrane proteins receptors containing α and β heterodimeric chains 
and a short tail in the cytoplasmic region. They possess adhesion properties that connect the 
cell to the cytoskeleton and are able to influence cell survival and cell death (Aoudjit and 
Vuori, 2012). They function in cell proliferation via signal transduction pathways by 
activating protein kinases (Giancotti and Ruoslahti, 1999). Integrins are expressed in 
primordial follicular cell surfaces, aiding their adhesion to the extracellular matrix. Integrins 
are weakly expressed in atretic tertiary follicles and absent in atretic primary and secondary 
follicles. Granulosa cells that lack the expression are the only ones that undergo apoptosis 
(Giebel et al., 1996).  Volociximab, a chimeric monoclonal antibody directed against α5β1-
integrin, inhibits angiogenesis and impedes tumor growth. Intetumumab (CNTO95) is a fully 
human anti–αv integrin monoclonal antibody that binds human αv integrin–expressing cells 
with high affinity (Kd, approximately 1–24 nmol/L) and has limited cross-reactivity with rat 
αv integrin (Kd, 220 nmol/L). Intetumumab has been reported to inhibit cell adhesion, 
migration, invasion, and proliferation of endothelial cells and tumor cells in vitro and tumor 
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metastasis in vivo in nude mice with human breast cancer xenografts by inactivating the focal 
adhesion kinase (FAK) and the docking protein paxillin (Chen et al., 2008). Intra-peritoneal 
administration Etaracizumab is a a humanized monoclonal antibody that has been tested in 
SKOV3ip1 and HeyA8 mouse model tumours, targeting the αvβ3 integrin receptor. This 
study showed a decreased tumour burden by 36 and 48% respectively (Landen et al., 2008). 
However, its role in ovarian cancer patients is still to be exploited in clinical trials. 
Cilengitide, an αVβ3 and αVβ5 inhibitor, is a cyclic RGD containing pentapeptide. 
Cilengitide has been shown to cross the blood brain barrier and accumulate to appreciable 
levels in brain tissue in a phase 2 trial in glioblastoma. Perry et al. (2013) using breast cancer 
cell lines (MCF-7 cells and then MDA-MB-231) treated with Cilengitide has shown that it 
was able to induce apoptosis and arrest cell proliferation. Cilengitide target expression level 
may play a role in this process, and apoptosis appears to be possible mechanism for 
cilengitide mediated cell death in these cell lines. In another study by Lautenschlaeger et al. 
(2013), using breast cancer cell lines found that combined cilengitide and radiation therapy 
appears to be more efficacious than either treatment alone in breast cancer cell lines. This 
study together with others (Reardon et al., 2008) have actually supported the idea that 
cilengitide in combination with radiation can be useful tool against ovarian cancer associated 
with integrins. 
 
 Insulin-like growth factor (IGF): IGFs are proteins with high sequence similarity to insulin 
that stimulate mitosis; regulating cell proliferation, differentiation and apoptosis. IGF binding 
proteins regulate the activity of IGFs by modulating IGF binding to their cognate receptors 
(Werner et al., 2008). IGF-1 functions in the ovary by potentiating the action of 
gonadotrophic hormones.  IGF-1 stimulates and sustains signals that lead to cell proliferation 
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and inhibition of apoptosis by activation of the P13K/AKT pathway (Wang et al., 2007). A 
high IGF-1 expression in mice follicles suggests that it pays an important role in follicle 
development.  The roles of IGF binding proteins may differ; while IGFBP-4 is highly 
expressed in atretic follicles, IGFBP-5 is up-regulated in healthy primary and secondary 
follicles (Besnard et al., 1996). IGF over-expression correlates with poor disease prognosis in 
some cases of ovarian carcinomas (Brokaw et al., 2007). Small molecule inhibitors hinder the 
activation of IGF-IR by binding to the pocket of the receptor that binds to ATP. The 
attenuation of insulin receptor signalling is a side effect that is exhibited by most tyrosine 
kinase inhibitors that have been developed. Nonetheless, their activity in preclinical models 
has made them to be evaluated in clinical trials, irrespective of their lack of specificity. 
 NVP-AEW541 is a potent inhibitor of IGF-1R which was demonstrated to sensitized cells to 
the effect of cisplatin treatment in ovarian cancer cells (Beauchamp et al., 2010). NVP-
AEW541 induced apoptosis and decreased AKT activation (Beauchamp, et al 2010) in two 
human epithelial ovarian cancer cell lines, namely, OVCAR-3 and OVCAR-4. Another 
molecules exploited is, BMS-536924 which is a potent small molecule inhibitor of IGF-IR, 
which shows antitumor activity in multiple tumour models.  It has been reported to provoke 
cell apoptosis in ovarian cancer cells by the activating PARP cleavage (Xu et al 2008). In 
addition, it proposes that combination therapy using BMS-536924 with a PARP inhibitor 
might be an effective strategy to circumvent resistance to treatment in clinical settings. In 
another study by Beltran et al. (2009) using  AMG 479, a fully human monoclonal antibody 
against insulin-like growth factor type 1 receptor (IGF-1R)  they reported that AMG479 
served as second line therapy in patients with recurrent platinum-sensitive ovarian cancer by 
blocking the binding of IGF1 and IGF2. There is a possibility that these agents might be more 
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potent anticancer drugs since insulin receptor present on malignant cells may have an 
important role as well in carcinogenesis. 
 
Figure 1.2:  A schematic mechanism showing apoptosis in ovarian cancer and some current 
targeted therapeutic approaches. 
Central to this mechanism is the activity of gonadotrophins and other upregulated proteins 
such as Aurora A, PARP, mTOR and growth factors such as EGFR, VEGFR, and PDGFR 
which have been exploited as molecular targets in various types of epithelial ovarian cancer 
and are at various phases in clinical trials. The numbered red stars (1 to 12) represent various 
molecular targets that have been explored in ovarian cancer (See table 1.1). 1. Aurora A is a 
potent prosurvival molecule that exerts its effects by activating AKT, promoting DNA repair 
by activating BRCA1, blocking p53 activity, and activating the transcription factor NFkB.  
Growth factor receptors (EGFR (4), VEGFR (5), and PDGFR (6) which exert prosurvival 
effects via the P13K/AKT pathway and have been targeted in ovarian cancer. XIAP, which 
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can be upregulated by growth signals from NFkB is the most potent known inhibitor of 
caspases and has also been targeted using small molecules.  Intergrins such as α5β1-integrin 
exert prosurvival effects by activating protein kinases. IGF-1 functions in the ovary by 
potentiating the action of gonadotrophic hormones.  IGF-1 stimulates and sustains signals 
that lead to cell proliferation and inhibition of apoptosis by activation of the P13K/AKT 
pathway. MDM2 which interacts with RBBP6 to promote p53 ubiquitination has been 
targeted as well with Nultin-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
Table 1.1 
A table showing small molecule inhibitors/ monoclonal antibodies and their molecular 
targets in ovarian cancer 
Small molecule drug 
(generic name) 
Molecular Target Clinical Trial 
Phase 
References 
1. Tozasertib 
(MK-0457) 
Aurora kinase Phase I Sun et al., 2007, 
Lin et al., 2008, 
Traynor et al., 
2011 
2. Nultin-2 MDM2 Phase I Wang et al., 2012 
3. Olaparib PARP (Poly-ADP 
ribose) 
Phase I Fong et al., 2008 
4. Erlonitib and 
gefitinib 
EGFR (epidermal 
growth factor 
receptor) 
Phase II (gefinitib) 
Phase III (erlonitib) 
Schilder et al., 
2005, 
Vergote et al., 
2013 
5. BMS-690514 VEGFR (vasculo-
endothelial growth 
factor receptor) 
Not yet entered 
clinical trials for 
ovarian cancer 
Becker et al., 
2013 
6. Imatinib 
mesylate 
(STI57) 
PDGFR (Platelet-
derived growth factor 
receptor) 
Phase II Alberts et al., 
2007 
7. Everolimus 
(RAD001) 
mTOR Phase I Mabuchi et al., 
2007, Okamoto et 
al., 2010 
8. APR-246 P53 Phase II Von Euler et al., 
2014 
9. LBW242 XIAP Phase I Eschenburg et al., 
2012; Petrucci et 
al., 2012 
10.  Integrin  Not entered clinical 
trials for ovarian 
cancer 
Landen et 
al., 2008 
11. BMS-536924 
          NVP-AEW541 
       
Ganitumab (AMG-479) 
IGFR1 Not entered clinical 
trials for ovarian 
cancer 
 
Phase I 
Xu et al 2008; 
 
Beauchamp et al., 
2010 
 
12. ABT-737 Bcl-2 Phase I Jain  et  al., 2014   
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1.8 Paclitaxel and Camptothecin derivatives as conventional chemotherapy in 
ovarian cancer 
1.8.1 Paclitaxel 
 
Paclitaxel is a potent natural drug that was isolated from the bark of the western yew tree 
Taxus brevifolia and shown to possess antitumour and antileukaemic activity (Wani et al., 
1971). Paclitaxel primarily targets microtubules, which are vital for cell division, 
proliferation, secretion and motility (Holmes et al., 1991; George et al., 1992). Paclitaxel 
stimulates the assembly of microtubules, hinders microtubule depolymerisation and alters 
their dynamics (Rowinsky and Donehower, 1995).A disturbance of the dynamics of 
microtubules by mitosis-inhibiting compounds results in an inhibition of cell cycle 
progression with a G2/M phase growth arrest, eventually leading to apoptosis (Jordan and 
Wilson, 2004). Presently, paclitaxel is used for the treatment of ovarian and breast cancer 
however, challenges of drug resistance and undesirable side effects still abide (Copeland et 
al., 1994; Bartel et al., 2008). Gene expression changes in certain apoptosis-related genes and 
growth arrest genes such as have been observed, albeit the mechanism of apoptosis mediated 
by paclitaxel is not yet known (Ofir et al., 2001). 
Drug resistance observed in several anticancer therapeutics, including microtubule inhibitors 
such as paclitaxel, remains a huge challenge to cancer treatment (Copeland et al., 1994; 
Bartel et al., 2008). With increased understanding of the mechanisms of drug resistance in 
cancers, synthetic derivatives of paclitaxel are being developed to curb the problem of drug 
resistance. 
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1.8.2 Camptothecin 
 
Camptothecin induces apoptosis by inhibiting the human DNA topoisomerase I enzyme 
(Topo I) which is active in the S-phase of the cycle.  Topo I is involved in the cleavage and 
re-ligation step of DNA replication in eukaryotic organisms. Topo I relaxes the supercoiling 
of DNA as a result of torsional stress produced during DNA replication (Wang, 1985)  An 
abrogation of topo I function by camptothecin binding to the topoisomeras1/DNA complex 
results in DNA strand breaks which leads to apoptosis. (Liu et al., 2000) 
Mutations of DNA topo I have correlated with high resistance to camptothecin in some colon 
cancer cells (Arakawa et al., 2013). 
Paclitaxel and Topotecan (a derivative of camptothecin) have passed all phases of clinical 
trials and are currently being used for the treatment of advanced ovarian cancers (Ofir et al., 
2001) although resistance, recurrent disease and debilitating side effects still plague many 
patients. However, a combination of chemotherapeutics with RNA interference may improve 
upon patient management and clinical outcomes. 
 
1.9 RNAi as a targeted therapeutic approach 
 
Epigenetics is the study of heritable changes in gene expression without any changes in the 
corresponding coding sequence of DNA. Epigenetic modifications are effected by DNA 
methylation, histone modification and RNA interference (RNAi) (Egger et al., 2004). RNAi 
pathway is common in many eukaryotic organisms and plays an important role in defence 
against viral invading viral nucleotides and transposons, developmental changes and gene 
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expression (Fire, 1999). Central to RNAi are three types of small RNA molecules: micro 
RNA, shRNA and short interfering RNA (siRNA) (Bartel 2004; Peragine et al., 2004). 
siRNA technology has received a lot of attention in the scientific community and is currently 
widely applied in research (Yang et al., 2003; Moela et al., 2014; Ghaemimanesh et al., 
2014) 
1.10 siRNA structure and Mechanism of action 
 
With the exception of hairpin RNAs, double stranded RNA does not normally occur in 
eukaryotic organisms (Goodsell, 2008).Upon entry of parasitic double stranded RNA into the 
cell, the RNA binding domain of dicer, an RNase III endonuclease cleaves the dsRNA into 
approximately 22 base pairs fragments ). These fragments are called siRNA. (Typically each 
siRNA is a 20 to 25 bp double stranded molecule characterised by a 2 base pair nucleotide 
overhang and a hydroxyl group at the 3’ end, and a phosphate group at the 5’ end of each 
strand) (Goodsell, 2008) Dicer-siRNA is transported from the nucleus to the cytosol and 
integrated into argonaute proteins and the RNA induced silencing complex (RISC) is 
assembled. Arganaute then uses helicase activity to unwind the siRNA and retains one of the 
strands (the guide strand) while the other strand (passenger strand) is degraded. The guide 
strand, which is now a functional part of the RISC, recruits the RISC to the mRNA 
complimentary to the siRNA. siRNA recognition results in the catalytic degradation of the 
mRNA by the RNase domain of argonaute (Patkaniowska et al., 2004). As a result, 
translational inhibition of the target mRNA is accomplished. The ability for siRNAs to 
specifically knock down any aberrantly expressed gene makes them attractive molecules for 
targeted therapy in cancer.  
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This study employs siRNA technology to knock down the RBBP6 mRNA in RMG-1 ovarian 
carcinoma cells as a targeted therapeutic approach. 
 
1.11  The RBBP6 gene 
 
The RBBP6 gene is located on chromosome 16p11.2 to p12, and codes for a 250 kD protein 
which contains numerous repeated sequences. The protein possesses a conserved N-terminal 
RING finger domain, a highly conserved DWNN, an Rb protein binding domain and a p53-
binding domain (Sakai et al., 1995; Simmons et al., 1997). RBBP6 is a 250kD ubiquitin 
ligase protein than is known to interact with p53 and Rb proteins in humans and mice, both in 
vivo and in vitro (Sakai et al., 1995; Simons et al., 1997; Witte and Scott, 1997) and possibly 
regulating their levels. It is involved in mRNA processing and ubiquitin-like modification of 
proteins (Pugh et al., 2006). It enhances MDM2-mediated ubiquitination of p53 (Li et al., 
1997) and also plays a role in cell cycle regulation and cell differentiation (Scott et al., 2003). 
It is upregulated in numerous cancers such as lung cancer (Motadi et al., 2011), oesophageal 
cancer (Yoshitake et al., 2004), colorectal cancer (Chen et al., 2013), and cervical cancer 
(Mbita et al., 2012). RBBP6 suppresses p53 binding to DNA (Simmons et al., 1997), thereby 
inhibiting p53-dependent gene transcription.  
 
Figure 1.3: Structural domains of RBBP6. DWNN: Domain With No Name, ZINC, RING, 
NLS: Nuclear localisation signal, Rb BD: Rb binding domain, P53 BD: p53 binding domain. 
Adapted from Pugh et al., 2006.  
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1.12 Rationale of study 
 
RBBP6, which has now been shown to be expressed in a handful of cancers, binds to the 
tumour suppressors p53 and Rb; possibly sequestering them from the cell and hence 
promoting cell proliferation. It has been shown that endogenous RBBP6 interacts with 
MDM2 and enhances MDM2-mediated ubiquitination and degradation of p53 as a result of 
increased p53-MDM2 affinity (Li et al., 2007).  
 
 
Figure 1.4 shows a proposed mechanism by which RBBP6 interacts with MDM2 to mediate 
cell proliferation. 
 
Under normal physiological conditions, p53 is kept under tight regulation mainly by MDM2. 
Following stress an exposure of the cell to stress signals, such as DNA damage or oncogenic 
activation, p53 becomes activated by phosphorylation at specific residues. This 
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phosphorylation enables it to evade MDM2 mediated ubiquitination. Activated p53, 
according to the cellular context either leads to cell cycle arrest or apoptosis. However, 
upregulated RBBP6 may increase the MDM2-p53 affinity, thereby mediating enhanced 
ubiquitination and degradation of p53 by MDM2, which may lead to abnormal cell 
proliferation (Li et al., 2007).  
 
However, the mechanism by which RBBP6 promotes cell proliferation is unclear. Knocking 
down RBBP6 may indirectly improve upon the availability of the tumour suppressor, p53 and 
hence induce apoptosis. Paclitaxel and Camptothecin derivatives are currently used for 
treatment of ovarian cancers, albeit problems of resistance and relapse are frequently 
encountered (Niimi et al., 1992; Swisher et al., 1997). We wish to investigate the potential 
role of RBBP6 knockdown in apoptosis or cell proliferation and also evaluate the 
chemotherapeutic efficacy of Paclitaxel and Camptothecin by knocking down RBBP6. 
 
1.13   Aim and objectives 
Aim 
The aim of this study was to evaluate the anti-tumour activity of RBBP6 knockdown only, 
and in combination with paclitaxel and camptothecin-treated ovarian cancer cells  
Objectives 
The following are potentially achievable objectives of the research, which will enable us to 
achieve our primary aim. We intended to: 
1. determine whether silencing RBBP6 in ovarian cancer cells causes them to induce apoptosis 
in ovarian cancer cells. 
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2. evaluate the percentages of cell death by apoptosis, necrosis, and of viable cells when RBBP6 
silenced in ovarian cancer cells. 
3. determine and compare gene expression levels of MDM2, p53, Bax, Bcl-2 and p21 following 
RBBP6 knockdown 
4. evaluate cell cycle changes following siRBBP6 transfection 
5. compare gene expression and cell death levels in siRBBP6 transfected cells with cells co-
treated with siRBBP6 and paclitaxel or camptothecin.  
In order to achieve our objectives the following experiments or methodologies will be used: 
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CHAPTER TWO - MATERIALS AND METHODS 
 
2.1 Introduction 
 
This chapter elaborates on the techniques used to acquire results in this study. As much as 
possible, the basic principles of each technique, the procedures and protocols followed, and 
the reasons thereof are outlined herein. The following techniques were used:  
i)  Cell culture; including siRNA transfection, paclitaxel and camptothecin treatment 
ii) qPCR 
iii) Western blotting 
iv) xCELLigence® real time cell analysis 
v) Flow cytometry (Apoptosis) 
vi)  Flow cytometry (Cell cycle analysis) 
 
 
Figure 2.1 is a flow diagram illustrating the methods used to obtain results in this study. 
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2.2 Cell culture 
The cell line used in this study were RMG-1 cells, a clear-cell adenocarcinoma of the ovary 
were purchased from ATCC (American Type Culture Collection), Virginia, USA. 
 
2.2.1 Thawing and plating 
 
The frozen cells were thawed in a 37ºC water bath for one minute. The vials were then 
cleaned with 70% ethanol and transferred to a 15 ml centrifuge tube, and centrifuged at low 
speed for 5 min to remove the cryo-protectant, DMSO. The supernatant was discarded and 
the cell pellet resuspended in 5 ml of pre-warmed DMEM (Hyclone, USA) supplemented 
with 10% Foetal bovine serum (Highveld Biological, RSA) and 1% antibiotics (Penstrep) 
(Sigma Aldrich, USA).  Cells were cultured to 80% confluence at 37ºC in a humidified 
incubator maintained at 5% CO2 concentration. 
 
2.2.2 Sub-culturing  
 
The spent growth medium was aspirated and cells were washed twice with 1×PBS, pH 7.5. 
They were then trypsinised (Trypsin-EDTA, Biowest, France) for 2 min by gently adding 1 
ml of trypsin –EDTA. Resuspension of the cells was done by adding 3 ml of pre-warmed 
medium to stop protein degradation by trypsin.  The cells were gently pipetted up and down 
to enable even distribution and 10 µl were pipetted out and the cells counted using a 
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haemocytometer. They were then transferred to other culture flasks containing 7 ml of pre-
warmed culture media at their respective optimal seeding densities. 
 
2.2.3 Freezing 
 
 Freezing medium was prepared, composed of 20% FBS, 10% DMSO and 70% DMEM. The 
cell freezing procedure was as follows: Growth medium was aspirated; the cells were then 
washed twice with PBS and trypsinized. Trypsin was neutralised by resuspension of cells in 
normal growth medium. The cells were gently pipetted and 1ml of cell suspension was 
aspirated for cell counts and viability. The cells were centrifuged as earlier described and 
resuspended in appropriate amounts of cold cryopreservation medium based on cell counts 
and viability. 1 ml of cell suspension was transferred into sterile appropriately labelled 
cryovials which were then stored at -70ºC overnight. The following morning, the cells were 
transferred to liquid nitrogen for long-term storage. 
 
2.2.3 siRNA Transfection 
 
siRNAs were designed to target three regions of the RBBP6 mRNA (Dr. L. R Motadi) for 
effective knock down of the gene. They were synthesized by Ambion Inc., Huntingdon, UK. 
Proper controls for siRNA were used to ensure effective gene knockdown and control for off-
target effects, if any. A random double stranded oligonucleotide was used as a negative 
control. The transfection protocol was followed according to the manufacturers’ 
recommendations and optimized modifications. 
43 
 
  A 5000 cells/ml cell suspension was prepared per sample, using culture techniques 
described above.  The 30µl of transfection reagent (siPORT, Ambion) was diluted in 600 µl 
of OPTIMEM in an eppendorf tube and allowed to incubate at room temperature for 10 min. 
To make final concentration of 30 nm of RBBP6 siRNA per well (after addition of cell 
suspension), 22.5 µl of 20 µM of RBBP6 siRNA was diluted in 600 µl OPTIMEM. The 
siRNA was then mixed with the diluted transfection reagent and pipetted up-and-down 5 
times. The mixture was then allowed to incubate for 10 min at room temperature to allow for 
the formation of siRNA/transfection complexes. 200 µl of the siRNA/transfection complex 
was then dispensed per well in a 6-well plate. Finally, 2300 µl of the cell suspension was 
added into each of the wells. The plate was rocked back and forth a few times to enable even 
distribution of cells and the siRNA/transfection complex. The cells were incubated at 37ºC 
for 6 hours (in order for the siRNA to be transfected or delivered into the cells). 2 ml of 
DMEM containing 10% FBS was added per well to prevent any potential cytotoxicity, while 
enriching the growth medium for cell growth. Two negative controls were used in the assay: 
A negative control using 30nm of scrambled siRNA, and another negative control using the 
transfection reagent only (without siRNA) were done. This was to control for false positives, 
false negatives or any non-specific effects. The negative controls showed no difference in cell 
proliferation when compared to untransfected cells.  These controls confirmed that any 
growth changes experienced were due to the knockdown of the RBBP6 mRNA. The cells 
were incubated for 24 h prior to 24 h treatments for RNA extractions, and 48 h for protein 
extractions and flow cytometry.  
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2.2.4 Camptothecin and Paclitaxel Treatments 
 
The cells were then treated with 50 nM paclitaxel (Sigma Aldrich, USA) in DMEM and 
0.5µM camptothecin (Merck, USA) in DMEM for 24 hours.  
 
2.3 Real time PCR 
 
2.3.1 Introduction 
Numerous decisions concerning cell survival, proliferation, differentiation or death are as a 
result of changes in the patterns of gene expression (Zamorano et al., 1996). These changes in 
gene expression can be measured by using the polymerase chain reaction. The polymerase 
chain reaction is a highly sensitive molecular biology technique that is widely utilised in a 
vast array of applications to amplify specific template DNA sequences. mRNA levels can 
therefore be evaluated, which indicate important changes in gene expression following 
induced cellular stimuli such as drug treatments or transfections. The entire procedure 
involved RNA extraction, RNA purity and integrity evaluations, cDNA synthesis (reverse 
transcription), primer design and optimization and qPCR. 
 
 
Figure 2.2: Real-time PCR workflow 
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2.3.2 RNA extraction 
 
Total RNA was isolated from RMG-1 and MRC-5 using the Nucleospin RNA 2 (Promega, 
Wisconsin, USA) following manufacturers’ instructions. Recombinant DNAse was used in 
the procedure in order to degrade contaminating DNA in the RNA sample before elution of 
the RNA in nuclease-free water. 
RNA quantity, purity and integrity are very important parameters in PCR for reliable results. 
The RNA was quantified using the Nanodrop spectrophotometer (Thermofischer Scientific, 
California, USA) which also checks on RNA purity. 
Concentrations of RNA from the various samples were determined using a Nanodrop 
spectrophotometer to measure optical densities at a wavelength of 260 nm. RNA purity 
assessments were established by A260/280 of ~2.0 and A260/230 between 1.9 and 2.2.  
 
2.3.2.1 Denaturing agarose gel electrophoresis 
 
To check for RNA integrity, the RNA was run on a 1% formaldehyde denaturing agarose gel 
stained with ethidium bromide. This was to make sure the RNA used was not degraded. In 
this procedure, 1 g of agarose was weighed and dissolved in 72 ml of DEPC-treated water. 
The agarose was melted by microwaving at high power for 1 min. 10 ml of 10X MOPS 
buffer was added and the mixture allowed cooling to about 60 degrees. 18ml of 37% 
formaldehyde was added to the mixture and mixed thoroughly in a fume hood. The gel was 
then poured and allowed to set. 
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The RNA sample was prepared by adding 5µl of DEPC-treated water and 15 µl of RNA 
sample buffer to 5 µl of RNA sample. The sample was heated to 65 degrees for 10 min and 
allowed to cool on ice for 3 min. The samples were loaded in the gel immersed in 1X MOPS 
buffer and run at 100V for 1.5 hours.  The gel was viewed in a Gel Documentation (Biorad, 
CA, USA), showing the 18S and 28S, 18S and 5S rRNA subunits; therefore attesting to a 
satisfactory level of RNA integrity. 
 
2.3.3 Reverse transcription (cDNA synthesis) 
 
Reverse transcription was done using the Improm II reverse transcription kit from Promega 
(Promega, Wisconsin, USA) to synthesize cDNA from total RNA to be used for PCR. The 
reaction was carried out in a 20 µL reaction mixture, made up of a cocktail of the following: 
1.4 µl (1µg) of total RNA, 1 µl of reverse transcriptase, 1 µl RNase inhibitor 2.5 µl of oligo 
dt primers, 2 µl of DNTPs, 3 µl of MgCl2 and 7.5 µl of nuclease-free water.   
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Table 2.1 
cDNA synthesis reaction components 
Reagent Volume  Final 
Concentration/mass 
RNA 1.4µl 1 µg 
Reverse 
transcriptase 
1 µl _ 
DNTPs 2 µl 1Mm 
Oligodt primers 3 µl 75µg/ml 
MgCl2 3 µl 3.75mM 
RNAse inhibitor 1 µl              _ 
Nuclease-free 
water 
7.1µl             _ 
Final volume 20 µl            _ 
 
The samples were then placed in the Gene Amp thermal cycler 2700 (Applied Biosystems, 
USA) and set sequentially to the following thermal conditions: sample denaturation at 95ºC 
for 5 min, annealing of primers to mRNA at 25ºC for 10 min, cDNA synthesis at 42ºC for 60 
min, enzyme (reverse transcriptase) inactivation at 95ºC for 10 min and sample cooling at 
4ºC. 
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Table 2.2 
Reverse transcription thermal cycling conditions 
 
Step Temperature/ºC Time 
Denaturation 95 ºC 5 min 
Annealing 25 ºC 10 min 
Extension/synthesis 42 ºC 60 min 
Enzyme inactivation 95 ºC 10 min 
Cooling   4 ºC ∞ 
 
 
2.3.4 Primer design 
 
Specific primers for the amplification of the mRNA for GAPDH, RBBP6, MDM2, p53, Bcl2, 
and Bax were designed using the NCBI website. Important parameters such as melting 
temperature, GC content, primer length and 3’complimentarity were taken into consideration 
for optimal results. The sequences were then sent to Whitehead, SA for oligonucleotide 
synthesis. 
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Primers 
 
Table 2.3 
Gene Forward primer  Reverse primer Amplicon 
sizes/kbp 
GAPDH 5’-TGTAGTTGAGGTCAATGAAGGG-3’ 5’-ACATCGCTCAGACACCATG-3’ 143 
Bax 5’-AAAGATGGTCACGGTCCAAC-3’ 5’-CAAACTTGGTGCTCAAGGC-3’ 36 
Bcl-2 5’AGCCAGGAGAAATCAAACAGAC-3’ 5’-GATGACTGAGTACCTGAACCG-3’ 117 
MDM-2 5’-GTGCATTTCCAATAGTCAGCTAA-3’ 5’-AGAAGGACAAGAACTCTCAGATG-3’ 129 
TP53 5’-GACGCTAGGATCTGACTGC-3’ 5’-GACACGCTTCCCTGGATTG-3’ 155 
RBBP6 5’-ACGAAGAACCACTATAGGGAGA-3’ 5’- GCAGACAGCTCATTCAAATACC -3’ 122 
P21 5’-AAGACCATGTGGACCTGT-3’ 
 
5’-GGTAGAAATCTGTCATGCTG-3’ 
 
133 
 
 
 
2.3.4.1 Primer optimisation 
 
PCR was used to ascertain that our designed primers could effectively amplify our target 
gene products without the formation of primer dimers. Our primers were optimised by testing 
a range of annealing temperatures with various magnesium ion concentrations. The reaction 
was carried out in a 20µl mixture containing the following: 10µl Master Mix (Promega, 
Wisconsin, USA), 1µl forward primer, 1µl reverse primer, 1µl cDNA, 1.5µl (1.5µM) MgCl2 
and 5.5µl of nuclease-free water. The samples were then run in a Gene Amp thermal cycler 
(Applied Biosystem , USA), with the following thermal cycling parameters:  
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 Table 2.4  
Thermal cycling parametres for PCR 
                                                                                                                 
The PCR products were run on a 1% agarose gel to confirm the product sizes and ascertain 
that no primer dimmers were formed. All primers worked at 60ºC. 
 
2.3.5 qPCR 
 
Following optimization of primers, qPCR was run in a 96 well non-skirted PCR plate 
(BIOplastics BV, Netherlands).  In order to monitor and quantify the amplification of cDNA 
from the various samples in real time, Maxima SYBR
®
 green/ROX qPCR master mix 
(Thermoscientific, USA) was used.  The master mix includes Maxima
® 
Hot Start Taq DNA 
polymerase, dNTPs and an optimised buffer. It also contains SYBR green I dye and a ROX 
passive reference dye. Primers, cDNA and nuclease-free water were then added to the master 
mix in the right proportions per sample.  To minimise variability, cocktails were prepared 
containing SYBR green, primers and water. 1µl of cDNA was then finally added per well and 
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1 µl of nuclease-free water per NTC wells. A NTC was made for each primer set, containing 
all reagents except cDNA. 1 µl nuclease-free water was added in the place of cDNA for all 
‘no template’ controls. 
 
Table 2.5 
qPCR reaction reagents 
Reagent Cocktail Volume/µl  per tube Final Concentration 
SYBR Green 75 5                      _ 
Forward primer 7.5 0.5 50 nM 
Reverse primer 7.5 0.5 50 nM 
Nuclease-free 
water 
45 3                       _ 
Cdna    _ 1 100 ng/µl 
Total volume 145 10                        _ 
 
The plate was loaded into a Lightcycler qPCR machine, LC 480 (Roche, USA). Thermal 
cycling conditions were entered following recommendations from the SYBR green 1 protocol  
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Table 2.6: qPCR Thermal cycling parametres 
 
 
 
2.4. SDS PAGE and Western Blot 
2.4.1 Introduction 
 
Western blotting (immunoblotting) is a sensitive biochemical method that makes use of 
specific antibodies to identify specific proteins from a mixture of proteins that have been 
separated by SDS-PAGE. It makes use of three aspects: i) Separation of proteins by size, ii) 
transfer of proteins to a membrane and iii) using proper primary and secondary antibodies to 
tag the target protein and iv) using immunochemical substrates to visualise the proteins 
(Mahmood and Yang, 2012). 
 
 
Figure 2.3: Western blot workflow 
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2.4.2 Protein extraction 
 
The cells were cultured in 6-well plates, siRNA-transfected and treated with 50nm paclitaxel 
and 0.5uM camptothecin as previously described. Spent growth medium was aspirated and 
the cells were washed twice with cold 1X PBS. 0.5ml of RIPA buffer (Thermofischer 
Scientific, Massachusetts, USA) was added per well for cell lysis. The plate was then put on 
ice and gently agitated periodically to ensure even distribution. After 5 min, the wells were 
rapidly scraped to lyse and remove any residual cells. The cell lysates were transferred to 
1.5ml eppendorf tubes. The cell lysates were clarified by centrifugation at 14000g for 15 min 
at 4ºC. The supernatant, containing proteins were carefully transferred to 1.5ml eppendorf 
tubes on ice. The proteins were then stored at -80ºC.  
2.4.3 Coomassie blue staining and destaining 
 
In order to confirm a successful extraction of proteins, the proteins were run on a 12% SDS-
PAGE gels. Protein samples were prepared by adding 10µL of protein suspension to 10 µL of 
2X Laemmli sample buffer (Biorad, California, USA). The sample was heated on a heating 
block at 95°C for 7 min in order to denature the proteins. The samples were loaded into the 
SDS PAGE gel wells and run using a 1X Tris/glycine/SDS running buffer. Power parameters 
were set at 100V, constant voltage and 300mA of current for 2 hours.  The gel was then 
stained with coomassie solution overnight. The following morning, it was destained using 
destain solution for one hour. Protein bands were visualised, confirming a successful isolation 
of proteins. 
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2.4.4 BCA assay 
 
In order to load known concentrations into the SDS-PAGE gels, protein quantification was 
done using the Bichiconinic assay (BCA) protein kit (Thermoscientific, Massachusetts, 
USA). The Bichiconinic assay BCA protein assay colorimetrically detects and measures total 
protein. It relies on the reduction of Cu
2+
 to Cu
+
 ions in alkaline conditions by protein 
molecules, resulting in a pale blue colour. The amount of Cu
2+
 reduction is proportional to 
the amount of protein present. The Cu+ ions then form complexes with BCA molecules, 
producing a purple product which can be quantified spectrophotometrically at 562nm. It is 
more sensitive and less time-consuming, compared to other protein quantification assays. 
Eight BSA protein standards (25, 125, 250, 500, 750, 1000, 1500, and 2000 µg/ml) were 
prepared. Distilled water was used as the blank. 10ml of working reagent was prepared by 
adding reagent A to reagent B in a 50:1 ratio. 25µl of each of the BSA standards and 
unknown protein samples were pipette into different wells of a 96-well plate. 200µl of the 
working reagent were then added to each of the wells. The plate was then mixed thoroughly 
on a shaker for 1minute. It was then incubated at 37ºC for 30 min, after which the plate was 
cooled and the absorbance was read at 562 nm. The corrected absorbance values were gotten 
by subtracting the absorbance of standards and unknown samples from that of the blank. A 
standard curve of absorbance versus concentration was then plotted and the values of 
unknown samples were gotten by manual extrapolation. 
 
2.4.5 SDS-PAGE  
An 8% SDS-PAGE gel was prepared for RBBP6 (because of its large size of 250kD) and 
a12% gel was prepared for b actin, mdm2, Bcl-2, Bax, and p53. 30µg of total protein was 
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added to 10µl of 2X Laemli sample buffer (Biorad, USA). The sample was heated at 95ºC for 
7 min in order to denature the proteins. The samples were loaded per well for every sample. 
The gels were run in 1X running buffer at 100V, constant voltage for about 2hours.  Protein 
bands were confirmed by coomassie staining.  
 
2.4.6 Transfer 
 
Following SDS-PAGE, the gels were equilibrated in transfer buffer (containing Tris, glycine 
and 10% methanol) for 15mins on a rocking platform. Six filter papers and a 0.2µm pore 
nitrocellulose membrane (Biorad, California, USA) were cut, having approximately the same 
dimensions of the gel. The filter papers and membrane were briefly soaked in transfer buffer. 
The sandwich was then prepared in the following manner: 
A fibre pad soaked in transfer buffer was laid on the negative side of the cassette; three filter 
papers were then placed on the fibre pad. The gel was carefully placed on the filter paper 
after which the membrane was placed on the gel. Finally, 3 filter papers were then carefully 
placed on the membrane. Air bubbled were avoided by rolling a 15ml tube gently on the 
sandwich. The cassette was then clipped tightly and fitted into the transfer tank. Transfer 
buffer was poured into the tank up to the blotting mark. The transfer was carried out at 25 
volts at 4ºC overnight. Effective transfer was confirmed by washing the membrane in 
distilled water, and staining with Ponceau stain for 30mins. The membrane was then 
destained and blocked with 5% non-fat milk in TBS containing 1% tween (TBST) for 1hour 
at room temperature. The membrane was washed 5 times (5 min per wash) with 5ml TBST.  
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2.4.7 Antibody incubation: Antibodies, dilutions and preparations 
 
Monoclonal antibodies for Bax, Bcl-2, p53, RBBP6, MDM2 and β-actin were purchased 
from Santa Cruz Biotechnology, USA. Rabbit anti-mouse Horse radish peroxidase-linked 
(HRP-linked) secondary antibody was purchased from Cell Signalling technology, USA. The 
membranes were incubated with 10ml of 1µg/ml (diluted in TBST) of primary antibody 
overnight at 4ºC. The following morning, the membrane was washed 5 times (5 min per 
wash) with 5ml TBST. 10ml of 1µg/ml of Secondary antibody diluted in TBST containing 
5% non-fat milk was then added onto the membrane and incubation at room temperature was 
done for one hour. Final washes were then performed as above, with the membrane left in the 
final wash solution.  
 
2.4.8 Immunodetection  
 
The final wash solution was poured off the membrane and 1 ml each of chemiluminescent 
solutions A and B (Santa Cruz, USA) were mixed in a 15ml tube and dispensed to evenly 
cover the surface of the membrane. The membrane was incubated in the dark for 5min at 
room temperature. HRP linked to the secondary antibody catalyses the oxidation of luminol 
substrate present in solutions A and B, using hydrogen peroxide as an oxidizing agent,  
accompanied by an emission of low intensity light at 428nm (Veitch, 2004).   The emission 
of light was visualised on the Chemidoc imaging system. (Biorad, California, USA).  
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2.5 xCELLigence® Real Time Cell Analysis 
 
 The xCELLigence Real Time Cell Analyser (RTCA) (ACEA Biosciences, USA) system is an 
automated, electrical impedance-based, label-free electronic technology that measures 
cellular adhesion, invasion and proliferation in real-time. In the xCELLigence system, 
adherent cells generate electrical impedance whose measurements are converted to cell 
indices by the RTCA software. The cell indices are a measure of the cell numbers, viability, 
adhesion and morphology. This novel system is currently being explored in a wide range of 
biomedical applications to obtain and assess distinct cytological profiles. 
Cells were trypsinized and resuspended in Opti-MEM (Gibco, USA) at 5,000 cells per well. 
Opti-MMEM is a reduced serum medium that shows better transfection efficiency than 
serum-rich culture media (Young et al., 2004). 100 µl of cells, to be transfected were 
dispensed into 6 wells of an E-plate 16, containing prepared siRNA/transfection complex.   
The layout page on the software was completed; indicating cell type (RMG-1), cell number 
per well (5000), and concentration of treatments (paclitaxel: 50nM and Camptothecin: 
0.5µM).  
The experiment schedule page was then completed. The experiment was scheduled to run in 
steps; with manual intervention  involving unclamping the E-plate 16 from the RTCA 
instrument, performing cell culture tasks, re-clamping the plate on the RTCA instrument and 
clicking the “run” icon on the software were necessary to proceed to the next step. The first 
step measured background measurement of culture media only in each of the 16 wells of the 
E-plate. The second step was scheduled to run for 8 hours, to allow for siRNA transfection 
into the cells. 100µL of DMEM was then added to all the wells in order to inhibit any 
potential cytotoxic effects of the siRNA/transfection reagent complexes, and also to enrich 
the growth media for optimal cell growth. The third step was scheduled to run for 48hours, 
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monitoring post-transfection changes in cell proliferation. The growth media was then 
aspirated, the cells were washed and 50nM paclitaxel and 0.5µM camptothecin were added in 
designated wells. The fourth step was set to run for 24hours, evaluating treatment and 
transfection effects cell proliferation in real time. 
 
Table 2.7 
xCELLigence® RTCA experiment schedule 
              Step Sweeps  
Interval in 
min  
Approximate 
Duration per 
step 
Total  
Time 
 
1. Background 
measurement 
1  
1 
 
    1 minute 0:01:00 
 
2. siRNA 
transfection 
33         15 
 
    8 hours 8:23:54 
 3. Adding DMEM 193  15 
 
48 hours 55:08:36 
 
4. Treating with 
0.5µM 
Camptothecin 
and 50nM 
paclitaxel 
100  
15 
 
 
24 hours 80:09:47 
 
 
2.6 Flow Cytometry 
2.6.1 Introduction 
 
Flow cytometry in cell biology is a biophysical technique that measures and analyses 
physical properties of cells as they flow in a fluid medium bombarded by a laser beam. The 
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cellular characteristics measured and analysed include size, granularity, and fluorescence 
(Brown and Wittwer, 2000). In this study, we used flow cytometry to assess apoptosis, 
necrosis and cell cycle analyses. The cells are fluorescently labelled, excited using lasers such 
that they emit varying wavelengths of light. 
Phosphatidyl serine (PS) is a cell membrane phospholipid that plays an important role in cell 
cycle signalling, especially in response to apoptosis. During the early phases of apoptosis, PS 
which is embedded within the plasma membrane of live cells becomes translocated to the 
external surface of the cell membrane. The externalisation of PS is used as a marker of early 
apoptosis. Annexin V is a calcium ion-dependent protein that has a high binding affinity for 
PS (Andree et al., 1990).  Annexin V coupled to the green fluorescent dye, FITC can be used 
to assess the level of apoptosis using a flow cytometer (Koopman et al., 1994). Plasma 
membrane integrity becomes compromised during necrotic cell death. This exposes DNA. 
The exposure of DNA is taken advantage of by the DNA-binding dye, propidium iodide, as a 
marker of necrosis.  Proper gating procedures to count cell populations and not debris, and 
fluorescence compensations were done because of similar emission profiles of both FITC and 
PI dyes. This was done by having some cells which were unstained, Annexin V-FITC only-
stained, PI only- stained, and Annexin-V and PI-stained. 
 
2.6.2 Method 
2.6.2.1 Cell cycle analysis 
 
Cell cycle analysis using DNA-binding dyes such as Propidium iodide (PI) make use of the 
fact that DNA contents change as the cell progresses from the G1, S and G2 phases of the cell 
cycle. Cells that are in the S-phase of the cell cycle have more DNA than those in the G1.  
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While G2 cells have approximately doubled the amount of DNA found in G1 cells. For cell 
cycle analysis, cellular DNA content is measured using the DNA-binding dye, PI. PI 
intercalates into the helical structure of DNA. The amount of PI binding to DNA, hence the 
amount of fluorescence yield is directly proportional to the amount of DNA present within 
the cell (Brown and Wittwer, 2000). This makes it easy to detect cells that have undergone 
growth arrest at any phase of the cell cycle. 
 
2.6.3.1 Fixation of cells for cell cycle analysis 
 
Fixation of the cells was done using 70% (v/v) ethanol. Ethanol is a dehydrating fixative 
agent which also permeabilizes the cells to allow for the binding of PI to DNA. The cells 
were transfected and treated and harvested with trypsin following the routine procedures into 
a 15ml tube. The cells were pelleted by centrifugation at 1500 rpm for 10min. After removing 
the supernatant, the cell pellet was carefully resuspended in 1ml of PBS and transferred to a 
1.5ml eppendorf tube and centrifuged for 5 mins at 5000rpm. The PBS supernatant was 
gently removed and the pellet was carefully resuspended in 300µl of PBS. 700 µl of 100% 
ethanol, pre-chilled at -20ºC was added per sample and mixed by inverting the tube 5 times to 
ensure proper mixing and fixing. The cells were stored at -20ºC until required. 
 
2.6.3.2 PI Staining. 
 
The cell suspension was centrifuged at 5000g for 5 min, after which the supernatant was 
removed. The pellet was then washed twice with 1 ml of PBS by centrifuging at 1500rpm for 
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7 min per wash. The PBS supernatant was discarded and the cell pellet resuspended in 300µl 
of PI containing RNase and vortexed for 30seconds. The cell suspension was then incubated 
in the dark for 30 min, after which analysis was done at 488nm using a BD Acuri C6 flow 
cytometer (BD Biosciences, USA). 
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CHAPTER THREE-RESULTS 
 
3.1 Introduction 
 
 In this study, our aim was to investigate the effects of silenced RBBP6 on ovarian carcinoma 
cells combined with standard chemotherapeutic regiments. Interesting results were observed 
through the use of qPCR, xCELLigence RTCA, Western Blotting and Flow Cytometric 
analysis. Both apoptosis and cell cycle progression investigations were carried out using a 
Flow cytometer. All siRBBP6 transfections were carried out using 30nm of RBBP6 siRNA.  
 
3.2 The effects of RBBP6 knockdown, camptothecin and paclitaxel treatments on Bcl-2, 
Bax, MDM2 and p53 mRNA gene expression.  
 
To evaluate the role played by RBBP6 knockdown on the expression of certain key 
proliferative and apoptotic genes, qPCR was carried out. We evaluated the afore-mentioned 
genes because of the role they play in cell death or proliferation  
GAPDH gene was used as a reference gene to normalise gene expressions. Gene expressions 
were normalised to one; meaning expression levels above one showed that the gene in 
question was upregulated while expressions below one showed that the gene was 
downregulated. Bax mRNA expression was very low in this study; at protein level, Bax was 
not expressed. Bax expression did not change following RBBP6 knockdown. Melting curves 
were generated to confirm the melting points of the expected qPCR products. No template 
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controls were used as negative controls to ascertain that the products were not primer dimers 
but expected amplification of mRNA of interest. Samples were all run in duplicates in order 
to obtain significant statistical data. The REST (Relative Expression Software Tool) from 
Qiagen, Germany, was used to analyse the results at 95% confidence interval (P<0.05) using 
a two-tailed t-test. 
 
 3.2.1 mRNA expression analyses following RBBP6 siRNA transfection 
 
We first had to ascertain the effective knockdown of the RBBP6 gene. As seen in Figure 3.1, 
RBBP6 was downregulated by a mean factor of 0.446 (or a 55% downregulation). Our 
knockdown was therefore partly confirmed by reduced RBBP6 expression following RBBP6 
siRNA transfection.  A down regulation of RBBP6 gene expression was expected because the 
gene was knocked down. Since not all mRNA changes can be translated into functional 
protein products, we had to further ascertain the effective knockdown of RBBP6 at protein 
level, using a western blot.  
The following gene expression changes were observed after RBBP6 knockdown: 
Bax, MDM-2 and p21 did not show any significant change in mRNA expressions. P53 
showed an upregulation by a mean factor of 8.785 while Bcl-2 was downregulated by a mean 
factor of 0.088.  
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Figure 3.1: A is a box plot showing changes in gene expressions following RBBP6 siRNA 
transfection. The boxes represent the interquartile range, or the middle 50% of observations. 
The dotted line represents the median gene expression while the whiskers represent the 
minimum and maximum observations. B is a histogram depicting a comparison between 
untreated and siRBBP6-transfected cells. The blue and the red bars represent relative gene 
expression ofsiRBBP6-transfected cells and untreated cells respectively. 
 
3.2.2 mRNA expressions following treatment with Camptothecin and co-treatment with 
siRBBP6 
 
Following treatment with camptothecin only, the following gene expression changes were 
observed: Bax, p21 and p53 all showed an upregulation by a mean factor of 2.173, 3.422 and 
19.16 respectively. MDM2 also showed an upregulation by a mean factor of 6.797. Bcl-2, 
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however, showed a downregulation by a mean factor of 0.06. RBBP6 gene expression did not 
show any significant change following camptothecin treatment. After RBBP6 siRNA 
transfections followed by Camptothecin treatments, the following gene expression changes 
were observed: Bax and P53 gene expressions were upregulated by mean factors of 1.149 and 
12.295 respectively. RBBP6 and Bcl-2 were downregulated by mean factors of 0.566 and 
0.022 respectively. However, p21 and MDM2 expressions did not show any significant 
change but it showed that p21 was up to a mean factor of 7.1 from a mean factor of 3.8 in 
camptothecin treated only as compared to in co-treatment. 
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Figure 3.2: Gene expression changes following Camptothecin compared to co-treatment 
treatment with siRBBP6 and camptothecin. A is a Box plot analysis showing gene 
expressions following 0.5µM camptothecin treatment for 24 hours while B is Box plot 
analysis showing gene expression changes following 30nM RBBP6 siRNA transfection for 
24 hours and 0.5µM Camptothecin treatment for 24 hours. C is a histogram depicting a 
comparison between untreated, CPT-treated and co-treatment with siRBBP6 and CPT 
treatment.  
Bcl-2 was further downregulated in co-treated cells (0.022) compared to cells treated with 
CPT only (0.06). 
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Bcl-2 was further downregulated in co-treated cells compared to CPT-only treated cells. 
However, p21, p53, Bax, and MDM2 still showed a higher expression level in CPT-treated 
cells only as compared with co-treatments using CPT and siRBBP6.  
 
3.2.3 mRNA expressions following Paclitaxel treatment and co-treatment with 
siRBBP6. 
 
The following gene expression changes were observed following paclitaxel treatment: 
Bax expression showed no significant change in gene expression. Bcl-2 and RBBP6 both 
showed a downregulation by mean factors of 0.053 and 0.418 respectively. MDM2, p21 and 
p53 genes were all upregulated by mean factors of 3.986, 2.321 and 9.126 respectively. 
Transfection with RBBP6 siRNA followed by Paclitaxel treatments showed the following 
differences in gene expression: Bax, Bcl-2 and RBBP6 genes were downregulated by mean 
factors of 0.459, 0.048 and 0.595 respectively. MDM-2 levels did not change significantly, 
while p21 and p53 were upregulated by mean factors of 3.568 and 8.028, respectively. 
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Figure 3.3: Gene expression changes following Paclitaxel treatment and co-treatment with 
siRBBP6 and Paclitaxel. A is a Box plot analysis showing changes in gene expressions 
following 50 nM paclitaxel treatment for 24 hours while B is a Box plot analysis showing 
gene expression changes following 30nM RBBP6 siRNA transfection for 24 hours and 50 
nM paclitaxel treatment for 24 hours. C is a histogram depicting a comparison between 
untreated, paclitaxel-treated and co-treatment with siRBBP6 and Paclitaxel treatment. 
It can be seen on Figure 3.3 that there was a higher expression of p21 cells co-treated with 
siRBBP6 and paclitaxel (3.568) as compared to cells that were Paclitaxel-treated only 
(2.321). Bcl-2 was also further downregulated in co-treated cells (0.048) as compared to cells 
A B 
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treated with paclitaxel only (0.053). However, p53 showed a higher expression in cells 
treated with taxol only (9.126) as compared with co-treated cells (8.028).  
 
Following PCR, agarose gels were run, to ascertain that they were the expected product sizes 
 
Figure 3.4: Post-PCR gels. The figure shows PCR agarose gels run for the various genes. 
The arrows indicate “no template controls. 1-6 represent: untreated, camptothecin-treated, 
paclitaxel-treated, siRBBP6-transfected, siRBBP6 plus camptothecin, and siRBBP6 plus 
paclitaxel respectively. The intensities of the bands indicate whether or not there were any 
gene expression changes following siRBBP6 transfection and treatments with CPT and 
paclitaxel 
 
3.3 The effects of RBBP6 knockdown, camptothecin and paclitaxel treatments on Bcl-2, 
Bax, MDM2 and p53 mRNA protein expression. 
 
In order to analyse the effects of RBBP6 knockdown, followed by camptothecin and 
paclitaxel treatments on Bcl-2, Bax, MDM2 and p53 protein expressions, a western blot 
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analysis was carried out. We first needed to confirm that RBBP6 was indeed knocked down 
following RBBP6 siRNA transfection.  
 
 
Figure 3.5 Protein expression analyses. RBBP6, MDM2, p53, Bcl-2 and Bax protein 
expressions following RBBP6 siRNA transfections and treatments with camptothecin and 
paclitaxel. X and Y represent western blot analysis of the various proteins investigated. A, B, 
C and D are histograms showing densitometric analysis of the various protein bands of 
RBBP6, MDM2, Bcl-2 and p53 respectively. The lanes numbered 1 to 6 represent the 
following samples: 1: untreated samples, 2: Campthothecin-treated, 3: paclitaxel-treated, 4: 
RBBP6 siRNA-transfected, 5. siBBP6+ Camptothecin, 6. siRBBP6+ paclitaxel.  
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RBBP6 showed a 57% knockdown following siRNA transfection (Lane 4, compared to Lane 
1) which confirms that the protein was indeed knocked down.  30 µg of proteins were loaded 
per well. β-actin was used as a reference protein in this study. Bax, which is known to play a 
role in apoptosis, did not show any expressional changes at the protein level. Bcl-2, a pro-
survival protein showed reduced protein expression following RBBP6 knockdown, 
camptothecin and paclitaxel treatments. MDM2 was however upregualated following 
treatments and RBBP6 knockdown. 
 
3.4 xCELLigence® RTCA shows that RBBP6 knockdown, camptothecin and paclitaxel 
treatments reduce RMG-1 cell viability 
 
We needed to evaluate the role played by RBBP6 knockdown, followed by camptothecin and 
paclitaxel treatments on RMG-1 cell proliferation. We did an xCELLigence® Real Time Cell 
Analysis. This system analyses the proliferation of cells on a real time basis. Samples were 
run in duplicates and the curves averaged to control for any well-to-well variations. The plot 
displayed changes in cell indices (y-axis) against time in hours (x-axis). Changes in cell 
indices are a measure of changes in cell proliferation. 
 
3.4.1 Untreated and controls 
 
Negative controls with the transfection reagent only and another with non-specific or 
nonsense siRNA did not show any growth inhibitory effects when compared to the untreated 
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samples. This confirmed that the observed growth changes were as a result of RBBP6 siRNA 
transfections which led to the knockdown of the RBBP6 gene.  
 
Figure 3.6: An xCELLigence RTCA plot showing real time cell proliferation of untreated 
cells and controls over a period of 80 hours. The green curve shows untreated cells, the black 
curve shows cells treated with 30nM of non-specific siRNA, while the turquoise curve shows 
cells that were treated with the transfection reagent (siPORT) only.  
There was no significant difference in untreated cells compared with mock-transfected 
controls, enabling us to attribute any observed cell death to siRBBP6 transfection. Cell index 
measure as indicated by the growth curve all remained static after 54 hours suggesting that 
the cells were not growing anymore. 
 
3.5 siRBBP6 transfected cells compared to untreated cells 
 
Following RBBP6 siRNA transfection, cell proliferation reduced, as shown on the following 
figure: 
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Figure 3.7.1: xCELLigence RTCA growth curves showing siRBBP6 transfected cells 
compared to untreated cells 
 
 
Figure 3.7.2: xCELLigence RTCA plot showing real time RMG-1 cell proliferation changes 
following 30nM RBBP6 siRNA transfection over a period of 80 hours. The green curve 
shows untreated cells red curve shows RBBP6 siRNA-transfected cells. Figure 3.7.2 is a 
histogram that shows xCELLigence cell indices at 72 hours for untreated, negative control 
and siRBBP6 transfected.  
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 It can be seen on Figure 3.7.1 that siRBBP6 transfection caused a decrease in cell 
proliferation. This is shown by a relative decrease in cell indices of transfected cells (red 
curve) compared to untreated cells (green curve) over time. 
 
3.6 Camptothecin and Paclitaxel treatments 
 
 The following curves show real time cell proliferation following 0.5 µM camptothecin and 
50 nM paclitaxel treatments over 48 h. 
 
Figure 3.8: xCELLigence real time cell proliferation following 0.5 µM camptothecin and 
50nM paclitaxel treatments over 48 hours 
 
Figure 3.8: xCELLigence RTCA plot showing real time effects of 0.5µM camptothecin and 
50nM paclitaxel on cell proliferation. The green curve shows untreated cells, the red curve 
shows camptothecin-treated cells while the blue curve shows paclitaxel-treated cells.  
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Cell indices dropped following 4 hours of paclitaxel treatment showing decreased 
proliferation. However, after roughly 32 hours, cell proliferation remained constant, 
suggesting growth arrest.  
 
3.7 Cell proliferation after siRNA transfection, Camptothecin and Paclitaxel treatments 
 
Following siRNA transfections and Camptothecin and Paclitaxel treatments, the following 
cell proliferation curves were observed: 
 
 
Figure 3.9: xCELLigence RTCA plot showing real time effects of 30nM RBBP6 siRNA 
transfections for 48 hours, followed by 0.5µM camptothecin and 50nM paclitaxel for 24 
hours on cell proliferation. 
Following about 8 hours of siRBBP6 transfection, cell indices, which is a measure of cell 
proliferation as shown on the purple, blue and red curves were not as high as untreated cells 
(the green curve). Moreover, after CPT and paclitaxel treatments at 55 hours there was a 
short-lived growth spurt which lasted for 4 hours. The cell indices for CPT-treated cells post 
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siRBBP6 transfection plummeted till the end of the experiment (at 80 hours). A rather 
different growth pattern was observed when cells were treated with paclitaxel following 
siRBBP6 transfection. There was a decrease in cell proliferation up till 72 hours, after which 
there was a stable growth pattern for about 2 hours. Cell proliferation then began to increase 
steadily, after which it finally declined. 
 
3.8 Effects of RBBP6 siRNA transfections and paclitaxel treatments on the cell cycle  
 
Flow Cytometry (Cell cycle analysis) (Paclitaxel induces cell cycle arrest in RMG-1 ovarian 
cancer cells). Paclitaxel is known to induce growth arrest and apoptosis (Vikhanskaya et al., 
1998, Giannakakou et al., 2001) Cell indices dropped following 4 hours of taxol treatment 
showing decreased proliferation. However, after roughly 32 hours, cell proliferation remained 
constant, suggesting growth arrest. Also, the upregulation of p53 following RBBP6 
knockdown prompted us to investigate growth arrest, given that p53 is known to upregulate 
p21. P21, a growth arrest gene was upregulated in our qPCR following siRBBP6 and 
paclitaxel treatments. The afore-mentioned points prompted us to investigate the possible 
effects of RBBP6 knockdown and paclitaxel treatments on the cell cycle. 
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Figure 3.10: Effects of RBBP6 siRNA transfection and Paclitaxel treatment on the cell cycle 
of RMG-1 cells.  
Untreated cells showed 93.8% at the G0/G1 stage, 2.6% at the S phase and 2.0% at the G2/M 
phase. Cells treated with 50nM paclitaxel showed 19.6% at the G0/G1 phase, 3.0% at the S 
phase and 0.2% at the G2/M phase. Cells transfected with 30nM siRBBP6 showed 68.5% at 
the G0/G1 phase, 5.2% at the S phase and 0.0% at the G2/M phase. Cells that were both 
transfected and treated showed a G0/G1 percentage of 16.8 and an S phase percentage of 2.3 
and a G2/M percentage of 0.5. 
3.9 An evaluation of sub-G0/G1 populations following treatments, representing cell death 
 
Cells that showed a chromosome number of less than 2n appeared at the sub-G0/G1 cell 
population. This was an indication that their DNA had either been fragmented or smeared 
which could represent apoptosis or necrosis.  
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Figure 3.11: A histogram showing Sub-G0 cell populations showing cell death in untreated, 
paclitaxel treated (50nM), RBBP6 siRNA-transfected (30nM) and both transfected and 
treated.  
Cell death statistical significance was calculated using a two-tailed t-test at a 95% confidence 
interval on the GraphPad QuickCalcs statistical program 
(http://www.graphpad.com/quickcalcs/ttest1.cfm). P values of less than 0.0001 were obtained 
when the means and SE of untreated and RBBP6 siRNA-transfected cells were used. This 
showed a very strong statistical significance. When means and SE of paclitaxel-treated cells 
were compared to those which were transfected before treatment with paclitaxel, a P-value of 
less than 0.0001 was also obtained; showing a strong statistical significance. The mean ± SD 
of cell death showed the following: As compared to untransfected cells, the RBBP6 siRNA-
transfected cells showed a 37.0±5.8% while untrasfected cells showed a 1.9±0.4% cell death. 
Paclitaxel treated cells showed a 76±1.14% while cells that were both siRNA-transfected and 
paclitaxel-treated showed an 81.6±0.79% cell death. 
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CHAPTER FOUR- DISCUSSION 
 
4.1 Introduction 
 
Owing to the inadequate clinical benefits of conventional chemotherapy and surgery in 
ovarian cancer coupled with debilitating side effects, targeted therapeutic strategies have 
taken the centre stage in current research and clinical trials. In advanced stage ovarian 
cancers, standard treatment includes surgery, followed by chemotherapy with paclitaxel and a 
platinum based chemotherapy such as carboplatin or cislpatin (Markman et al., 2001). 
Moreover, the aqueous insolubility of camptothecin combined with severe and unpredictable 
side effects have impaired its therapeutic applications in cancer (Rothenburg, 1997).  
However, resistance and recurrent disease will occur in 80-85% of those diagnosed with 
advanced cases of ovarian cancer (Parkin et al., 2008).  
Targeted therapeutics are dependent on an understanding of normal and oncogenic signalling 
pathways in the ovaries, which are usually not easy to elucidate. Aberrantly expressed 
oncogenes and proteins are key molecular targets in cancer. Small molecule inhibitors and 
monoclonal antibodies have attracted a lot of attention in the treatment of ovarian cancer 
(Gera et al., 2004; Apte et al., 2004; Fong et al., 2008; Traynor et al., 2011). 
The RNAi pathway, which includes shRNA, miRNA and siRNA activity, is currently being 
exploited by biologists to investigate gene function (Moela et al., 2014; Ghaemimanesh et al., 
2014). Herein, we focused of a new mode of targeted therapy, in which an abnormally 
expressed gene, RBBP6, is knocked down by siRNA.  
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A very logical question in this study would be: “Why did we develop interest in RBBP6 in 
the first place?” RBBP6, because of its possession of a RING finger domain, has been 
identified as an E-3 ubiquitin ligase (Pugh et al., 2006). It is not surprising that RBBP6 is 
deregulated in several cancers (Yoshitake et al., 2004; Motadi et al., 2011, Mbita et al., 2012; 
Chen et al., 2013) because, a deregulation in ubiquitin pathways has been reported in 
numerous cancers (Hoeller et al., 2006).  The functions of RBBP6 which include cell cycle 
progression, its interaction with p53, Rb, which are all implicated in tumourigenesis, (Simons 
et al., 1997; Sherr and McCommick, 2002; Scott et al., 2003) chromosomal stability and 
preventing DNA damage (Miotto et al., 2013) coupled with its overexpression in a handful of 
cancers suggest that RBBP6 plays a pro-survival role in the cell. Two important questions 
needed to be answered in this study: Firstly, could siRNA-mediated knockdown of RBBP6 in 
RMG-1 cells lead to a cell death or a decrease in cell proliferation? Secondly, could there be 
synergistic therapeutic effects of co-treatment of RMG-1 cells with Paclitaxel and siRBB6? 
In other words, could siRBBP6 transfection potentiate Paclitaxel or Camptothecin-induced 
cell death? 
4.2  qPCR and Western blot analysis of gene and protein expressions. 
4.2.1 qPCR  
So far, qPCR is the most sensitive technique that can be used for the quantification of gene 
expression. We used the MIQE (Minimum Information for Publication of Quantitative Real-
Time PCR Experiments) guidelines which helped us to ensure the quality, integrity, and 
transparency of our qPCR experiments (Bustin et al., 2009). We evaluated the levels of Bax, 
Bcl-2, MDM2, p21, and RBBP6 because of the role they play in cell death or proliferation 
and the direct or indirect relationship they may have with RBBP6.  RBBP6 which is 
overexpressed in a handful of cancers has recently been shown to be one of the members of 
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the negative regulators of p53. RBBP6 has been shown to interact with p53, mediating its 
ubiquitination by MDM2 (Li et al., 2007) and MDM2 is well known to regulate p53 levels 
(Barak et al., 1993). The rigorous regulation of the action of p53 is critical for cell survival, 
death, or proliferation because of its ability to transactivate and repress several genes 
responsible for apoptosis and proliferation.  Bcl-2 is known to aid cell survival and promote 
proliferation. Bax is a p53-inducible gene that plays a role in increasing mitochondrial 
permeability, causing the release of cytochrome C. This leads to apoptosis via the intrinsic 
pathway (Spierings, et al., 2005; Elmore, 2007).  
The first role of qPCR was to ascertain the effective knockdown of RBBP6, following it 
siRNA transfection in the cells. The knockdown was confirmed, showing a 55% drop in 
expression. The expression of Bax, Bcl-2, MDM2, p21 and p53 were evaluated. Bax, p53 and 
p21 and MDM2 showed an upregulation following camptothecin treatment. Camptothecin is 
known to inhibit DNA topoisomerase I activity. An abrogation of topoisomeras I function by 
camptothecin binding to the topoisomeras1/DNA complex results in DNA strand breaks 
which leads to apoptosis (Liu et al., 2000). It is most likely that the induced apoptosis is as a 
result of p53-dependent pathways. This is because p53 has been shown to be upregulated 
following DNA damage, although its upregulation is usually as a result of post-translational 
modifications rather than by increases in its mRNA levels (Kanstan et al., 1991). MDM2, 
Bax and p21 can be transcriptionally upregulated by p53. In order to control the excessive 
tumour suppressor functions of p53, MDM2 is known to negatively regulate p53 by p53 
ubiquitination (Chene, 2003) 
There was a slight increase in p53 protein expression following co-treatments in comparison 
to either paclitaxel only or camptothecin treatments only. Also, there was a slight 
downregulation of the pro-survival gene, Bcl-2 expression in co-treatments compared to 
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treatments only. Bax/Bcl-2 ratios have been employed successfully to predict the fate of a 
cell (Raisova et al., 2001). A ratio of greater than one means that the cell will most likely die, 
while a ratio of less than one (showing that Bcl-2 expression is higher), indicated that the cell 
will most likely survive. Given that Bax expression was not seen at the protein level, we 
could not use mRNA expressions alone to justify the fate of our cells. However, 
densitometric analysis of Bcl-2 western blot showed that, Bcl-2 expressions dropped more in 
co-treated cells than in paclitaxel-treated cells.   
 
4.2.2 Protein evaluations by Western Blots 
 
An upregulation of mRNA transcripts in a cell is no guarantee that functional proteins are 
going to be synthesized. A lot of changes can happen to an mRNA following transcription, 
which explains why there may not always be correlation of mRNA expressions with actual 
protein expressions. Only approximately 40% of mRNA changes can show correlation with 
actual protein expressions (Maier et al., 2009; Abreu et al., 2009). The expression of proteins 
can be controlled at post-transcriptional, translational and regulation of degradation (Vogel et 
al., 2012). Following expressions at mRNA levels, we decided to investigate which genes 
were effectively translated into proteins, which could most likely be functional. Although 
Bax was upregulated following camptothecin, siRBBP6, and co-treatments, we could not find 
any Bax expression on western blots. This could possibly mean that the observed Bax mRNA 
transcripts were degraded and hence any observed cell death was Bax-independent. 
Although RBBP6 mRNA expression did not show any change following camptothecin and 
paclitaxel treatment, there was a significant increase in RBBP6 protein levels as seen in our 
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western blots. This suggests that RBBP6 protein was stabilized by post-translational 
mechanisms, rather than from de novo synthesis of its protein products. Nonetheless, the 
mechanism by which camptothecin or paclitaxel may upregulate RBBP6 protein expression 
was in this study is still unclear.  P2-PR is a 250kD an alternatively spliced form of the full 
length RBBP6 protein, lacking an exon that codes for a 34 amino acid peptide (Saijo et al., 
1995). Paclitaxel and camptothecin are known to induce DNA damage in cells (Shao et al., 
1999; Branham et al., 2004). Considering functions of P2-PR as cell cycle regulation (Gao et 
al., 2002; Scott et al., 2003), maintaining chromosomal stability and preventing DNA damage 
(Miotto et al., 2013),  it is plausible to suggest that P2-PR could be upregulated as a 
protective measure, in order to induce cell cycle arrest in cells whose DNA had been 
damaged following camptothecin and paclitaxel treatment. MDM2 protein expressions 
increased to 45, 30 and 75 folds in CPT-treated, paclitaxel-treated and siRBBP6-transfected, 
respectively. MDM2 is known to be one of the most potent negative regulators of p53 so far 
(Haupt et al., 1997; Mommand et al., 2000); thereby explaining why several therapeutic 
strategies have been developed to target the MDM2-p53 interaction. P53 and MDM2 use an 
auto regulatory feedback loop to regulate each other’s levels in which activated p53 
transcriptionally upregulated MDM2 and MDM2 in turn targets p53 for ubiquitination and 
proteosomal degradation (Picksley and Lane, 1993). Moreover, it is important to note that 
there was a significant upregulation of p53 proteins following treatments and siRBBP6 
transfection. Taken together, an upregulation of p53 as seen in this study induced an 
upregulation of MDM2 protein. The above observation is consistent with other studies (Barak 
et al., 1993; Picksley and Lane, 1993). Consequently, it is logical to suggest that MDM2 
levels were upregulated in response to increased p53 expressions following CPT, paclitaxel 
and siRBBP6 treatments.  
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Multiple pathways and genes are involved in regulating cell survival, proliferation or death; 
however, only a handful of genes were analysed in this study. The expression of pro-
apoptotic and growth arrest proteins as seen in this study should not be a conclusive 
indication of apoptosis or cell cycle arrest. Notwithstanding, evaluating the effects on cell 
proliferation thus became imperative. xCELLigence RTCA measured proliferation on a real 
time basis while an analysis of the cell cycle changes showed sub-G1 populations which were 
indicative of cell death. 
 
4.3 xCELLigence RTCA measurements of cell adhesion and proliferation 
 
Most cell death or viability/proliferation assays rely on end-point measurements for 
assessments following treatments. However, we used the xCELLigence RTCA system as our 
method of choice because of its superior ability to continuously monitor cell adhesion, 
attachment and proliferation on a real-time basis. From xCELLigence show that there was no 
significant difference between untreated and negative controls. When we analysed mock 
transfected to siRBBP6 transfected, we realized that there was a significant difference 
between cell growths or proliferation. From real-time analysis, we observed that 
camptothecin-treated at 24 hours after plating, cells showed a reduction in viability as shown 
by cell indices, approximately 7 hours after treatment. This reduction in cell proliferation 
continued progressively till the end of the experiment at 48 hours. This showed that the cells 
were highly sensitive to camptothecin. Cells that were treated with paclitaxel showed a rather 
different growth pattern. Cell growth seemed to be immediately arrested when the cells were 
treated. Cell indices dropped following 4 hours of paclitaxel treatment showing decreased 
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proliferation. However, after roughly 32 hours, cell proliferation remained constant, 
suggesting some form of resistance to paclitaxel or growth arrest.  
xCELLigence RTCA showed growth arrest following paclitaxel+siRNA and paclitaxel only 
which were also consistent with p21 expression. Paclitaxel is known to induce G2/M growth 
arrest (Vikhanskaya et al., 1998), or even G1 growth arrest at small concentrations 
(Giannakakou et al., 2001). However, cell cycle could not show much arrest because the cells 
were harvested for analysis when they had already past arrest to apoptosis. Cells that have 
been arrested at G1 or G2/M check points are most likely to commit apoptotic cell death in 
case their DNA is not cannot be repaired.  
 
4.4 Cell Cycle analysis following treatments and co-treatments 
 
The PI used in this study contained RNAse to enable the quantification of DNA only, given 
that PI also bind to RNA. PI binding to DNA is proportional to the content of DNA a cell 
contains. Cells at G0/G1 are expected to be diploid (2n), and will therefore bind the least 
amount of PI, as compared to S-phase cells which contain more than 2n, and G2/M phase 
cells which contain 4n nuclei. This enables the cells to form different peaks based on the 
phase of the cell cycle in which they are found.  The characteristic growth pattern displayed 
by xCELLigence RTCA suggestive of some form of growth arrest or drug resistance to 
paclitaxel, and existing literature confirming G2/M or G1 growth arrest (at low paclitaxel 
concentrations) properties of paclitaxel prompted us to investigate changes in the cell cycle 
following treatments and co-treatments. Also, the upregulation of p21 following paclitaxel 
and siRBBP6+paclitaxel treatments suggested that a G1 cell cycle arrest could be involved. 
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P21 is a growth arrest protein that initiates its effects by inhibiting the activity of kinases. Its 
upregulation, in our study could most likely be as a result of p53-dependent transactivation, 
given that p53 was also highly upregulated following paclitaxel treatments and co-treatments. 
Nevertheles, p21 has also been shown to show upregulation independent of p53 
transactivation (Park et al., 2000). In our study, we noticed only a slight decrease of G2/M 
cells following The reason cell cycle arrest was probably translated to apoptosis was based on 
the timing the cells were harvested.  
The amount of cells that were at the G2/M reduced from 2.2 in the untreated, to 0.2 in 
paclitaxel-treated cells, 0.0 in siRBBP6 treated cells and to 0.5% in cells co-treated with 
siRBBP6 and paclitaxel. We deduced that, following treatments, cells did not progress 
beyond the S-phase and were therefore arrested at both G1 and S phases. 
  
4.5 Evaluation of Sub-G1 Populations: An indication of Cell death 
 
We noticed a significant increase in sub G1 cell populations of: 1.9% in untreated, 37% in 
siRNA transfected, 76.9% and 81.6% in paclitaxel and co-treated (siRBBP6 and paclitaxel-
treated) cells respectively. Cells at sub G1 represent those having less than a diploid number 
of chromosomes in their nucleus (< 2n).  These could either represent a population of cells 
with either fragmented or smeared DNA, characteristic of apoptosis or necrosis respectively. 
 
 
87 
 
4.6 Possible mechanisms of cell death  
 
Although numerous studies indicate mutations in p53 in more than 50% of cancers (Chan et 
al., 2000) and many high grade carcinomas of the ovary are due to TP53 mutations, our study 
shows that p53 may most likely be in its wild type state. It may be important to sequence the 
protein to confirm that functional p53. Treatments showed upregulated p53 which correlated 
with apoptosis. The p53 pathway may be fine. P53 acts in concert with other oncogenes to 
modulate cell proliferation. Bax expression was not increased although other p53 downstream 
genes such as PUMA, NOXA, Bad, Bak which were not investigated in this study may have 
been upregulated. However, p53 also shows transcription-independent apoptosis in which it 
translocated to the mitochondria and promotes mitochondrial membrane permeability by 
forming complexes with pro-survival Bcl-2 and/or Bcl-Xl (Mihara et al., 2003) or directly 
activating Bax (Moll et al., 2005) which may also be the case.  Several proteins which have 
not been investigated in this study may be upregulated or downregulated as a result of our 
transfections and treatments; and are possibly involved other mechanisms of apoptosis in our 
ovarian cancer cells. Knockdown of RBBP6 showed a marked increase in p53 protein 
expression as seen also in other studies (Li et al., 2007).  
Apoptosis, which is a programmed and controlled mode of cell death, yielding no 
inflammatory response (Kerr et al., 1972), is the ideal mode of cell death expected in cancer 
therapy. Even though an apoptosis-based assay was not performed, it is plausible to infer that 
the observed cell death was most likely as a result of p53-mediated apoptosis. This is because 
of the following reasons: 
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1. siRBBP6 transfection led to an upregulation of p53 at both mRNA and protein levels. p53 
null mutations rescued cell death in  RBBP6 knock down embryos (Li et al., 2007). 
Showing that the observed cell death was p53-dependent. 
2. Paclitaxel is well known to induce apoptosis. This is as a result of its mechanism of 
action. Paclitaxel causes the stability of microtubules, thereby inhibiting microtubule 
polymerization. A disturbance of the dynamics of microtubules by mitosis-inhibiting 
compounds results in an inhibition of cell cycle progression with a G2/M phase growth 
arrest, eventually leading to apoptosis (Jordan and Wilson, 2004).  
3. Cells that lack RBBP6 experience chromosomal instability and spontaneous DNA 
damage (Miotto et al., 2013) which are hallmark trig/gers for apoptosis, suggesting one of 
the ways by which knockdown of RBBP6 may induce apoptosis. 
4. It was noted that MDM2, which is known to be transactivated by wild type p53 levels 
(Barak et al., 1993) was upregulated following transfections and treatments. Mutant p53, 
which is not potent enough to induce apoptosis, cannot be transactivated by p53 (Midgley 
and Lane, 1997). As a result we suggest that the upregulated levels of MDM2 were an 
indication of the presence of wild type p53. Taken together, it is plausible to infer that 
most of the cell death observed by co-treatment regimens of paclitaxel and siRBBP6 cell 
death was due to p53-dependent apoptosis. 
However, apoptosis-based assays are needed to confirm the assertion, given that the 
mechanism by which the action of siRBBP6 and paclitaxel could synergistically boost cell 
death is not yet understood. 
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4.7 Conclusions and Clinical Implications 
 
Our findings show that siRNA-mediated knockdown of RBBP6 induces cell death. siRBBP6 
alone induced approximately 37±% cell in RMG-1 cells.  In addition, paclitaxel-mediated cell 
death in RMG-1 ovarian cancer cells is potentiated by siRBBP6. Taken together, it is most 
likely that RBBP6 plays an important role in inducing or sustaining cell proliferation.  
To sum-up, we have shown that siRBBP6 transfection may act in a synergistic manner with 
paclitaxel to reduce tumour growth in ovarian RMG-1 ovarian cancer cells. On account of the 
upregulated levels of RBBP6 in numerous cancers, and resistance observed in chemotherapy, 
a combination of chemotherapy with paclitaxel or camptothecin and RBBP6 siRNA could be 
a possible therapeutic strategy in combatting ovarian carcinomas.  
Furthermore, small molecules have been designed that interfere with the MDM2-p53 
interaction. Bearing in mind that RBBP6 enhances the ubiquitination and degradation of p53, 
it is plausible that, combining siRBBP6 activity with MDM2-p53 inhibitors may also serve as 
a therapeutic strategy in tumours overexpressing RBBP6. 
It is clear that RBBP6 acts in concert with several proteins  to modulate cell survival; and it 
has been shown to be overexpressed in numerous cancers such as lung cancer (Motadi et al., 
2011), oesophageal cancer (Yoshitake et al., 2004), colorectal cancer (Chen et al., 2013), and 
cervical cancer (Mbita et al., 2012).  
 The question is: What is the precise mechanism by which RBBP6 interacts with MDM2 and 
other proteins to cause cell proliferation? Additional techniques, including study of protein-
protein interactions using techniques such as affinity chromatography, co-
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immunoprecipitation and mass spectrometry may be the way forward to elucidate the precise 
mechanisms involved.  
A lot of interesting findings involving proposed mechanisms of cancer development, drug 
resistance mechanisms and alternative therapeutic strategies in cancer treatment have been 
published.  
Several studies have shown that siRNA alone or co-treatment with siRNA and some form of 
conventional chemotherapy actually sensitizes cells to apoptosis and cell cycle arrest. Yang et 
al., 2003, showed that retrovirus-delivered siRNA mediated knockdown of the H-ras gene 
reduced tumour growth in a model ovarian cancer. siRNA-mediated knockdown of RBBP6 in 
MCF-7 breast cancer cells followed by camptothecin treatment showed improved apoptosis 
as compared to camptothecin treatment alone (Moela et al., 2014). Nishimura and colleagues 
in 2013, have shown that therapeutic synergy could be realized when ovarian cancer cells 
were treated with siRNA and miRNA targeting EphA2 proteins. Moreover, a decreased cell 
survival and increased apoptosis was shown in ovarian carcinoma cells following the 
knockdown of the sortilin gene with siRNA (Ghaemimanesh et al., 2014). However, several 
pathways have been shown to be deregulated in ovarian cancer. The knockdown of a single 
gene may not provide optimal therapeutic benefits in patients. Microarray analysis may 
provide aberrant expression patterns which could lead to the development of multiple siRNA 
combinations, targeting over-expressed genes. 
However, it is easy to jump into inaccurate conclusions whenever the validity of in vitro 
experimental results is not proven using in vivo conditions. The fact that numerous clinical 
trials have not been able to move through recommended phases before potential drugs 
become approved therapeutic use, gives credence to the previous assertion. Our lack of 
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understanding of the complex molecular mechanisms that precede neoplastic transformation 
necessitates further research in this intricate and fascinating field of science. 
 
4.8 Future directions 
 
 Evaluate co-treatment of siRBBP6 and paclitaxel on normal cells. This would enable 
us ascertain whether any serious cytotoxic effects could result following co-
treatments. 
 Also, and evaluation of co-treatment effects on a less aggressive ovarian cancer cell 
line would be necessary. 
 Confirm the mode of cell death elicited by co-treatments using apoptosis-based assays 
such as the Annexin V-FITC and PI apoptosis assay 
 Evaluate apoptosis elicited by camptothecin, compared with co-treatment with 
camptothecin and siRBBp6. 
 An elucidation of the molecular mechanisms by which RBBP6 interacts with MDM2 
and p53 to mediate cell proliferation using other techniques such as co-
immunoprecipitation, affinity chromatography and mass spectrometry would be 
necessary. 
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